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Abstract 
 
The Polycomb Group proteins (PcGs) are present in cells nuclei as two main repressive 
complexes named Polycomb Repressive Complex 1 (PRC1) and 2 (PRC2). Both have been 
involved in several cellular functions among which the ability to promote cellular 
proliferation is the main PcG feature that links their activity to cancer development. Both 
complexes are directly involved in repressing the transcription of the Ink4aArf locus that 
encodes for the tumor suppressive proteins p16 and p19/Arf (p14/Arf in humans), potent 
inhibitors of cell growth via the positive regulation of pRb and p53 functions. Thus, since 
the activity of both PRC1 and PRC2 complexes is frequently enhanced in different type of 
human tumors, inhibition of PcG function has been proposed for many years as a potential 
strategy for cancer treatment. Yet, the fact that the pro-proliferative role of PcG proteins 
depends on the repression of the pRb and p53 pathways, of which most if not all tumors 
are defective, generates a scientific paradox for the effectiveness of PcG inhibition in 
cancer treatment. In this thesis, with the help of my colleagues, (from now on referred as 
we) I will present data showing how PcGs genetic depletion dramatically impairs cellular 
proliferation independently on the expression of the Ink4a/Arf locus or p53 and pRb 
activities. We also genetically demonstrate, in cell culture and in vivo, that PcGs activity is 
required for both the transformation and the maintenance of the transformed phenotype 
obtained by expression of potent oncogenes such as H-RASV12 or c-MYC in cells 
defective for the pathways of p53 and pRb.  Finally we suggest a potential mechanism to 
explain the reduced proliferation/tumorigenic potential involving DNA replication control 
by PcG proteins. We show defects both in fork progression and fork symmetry along with 
increased replication origin numbers in PcGs knockout transformed cells. Collectively 
these data strongly support PcGs as master regulators of cellular proliferation and 
transformation independently on the impairment of main tumor suppressive pathways and 
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introduce a novel general mechanism through which PcGs regulate these processes. 
Overall this work supports PcGs as druggable targets in tumors where oncosuppressive 
pathways are de-regulated and proliferation, ergo DNA replication, is enhanced. 
 
Aims 
 
The aims of this thesis mainly consist in dissecting Polycomb proteins role in the 
regulation of cellular proliferation and transformation. Precisely we try to elucidate the 
contribution of the main subunits of the Polycomb repressive complexes to cellular 
proliferation and transformation using primary cell lines genetically defecting the main 
negative regulators of cell cycle and the most known tumor suppressor genes. This allows 
us to study whether Polycomb proteins may play a role in a situation of uncontrolled 
proliferation, the hallmark feature of tumors. We next investigate the role of these proteins 
in both formation and maintenance of tumors generated by primary cell lines defective in 
tumor suppressive genes and fully transformed with well-known potent oncogenes. Last 
we try to elucidate the molecular mechanism that links Polycomb proteins to both 
controlled and uncontrolled proliferation by analyzing transcriptional changes induced by 
Polycomb loss as well as followed by deeply investigating a putative role of Polycomb 
proteins in S-phase and particularly in DNA replication. 
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CHAPTER 1: Introduction 
 
1.1 Polycomb group proteins 
The group of Polycomb proteins (PcG) is a biochemically heterogeneous family classified 
by their ability to induce, when mutated, homeotic transformations in Drosophila 
melanogaster2-6.   Mutations of PcG proteins induce developmental defects that are all 
accounted by spatial-temporal deregulation of homeotic genes expression2. Trithorax 
Group proteins (TrxG) form a second class of developmental regulators that counteract the 
effects of PcG mutations. PcG and TrxG proteins act on common regulatory pathways and, 
at least from Drosophila studies, they are not involved in determining the ON and OFF 
state of target genes but they play an essential role in maintaining a pre-set repressed (PcG) 
or active (TrxG) transcriptional state throughout development functioning as pivotal 
factors in cellular memory3, 5, 6.  
PcG proteins are highly conserved in evolution. Orthologues can be found in plants, 
worms, insects, amphibians, fishes and mammals and in all classes PcGs exhibit important 
developmental functions2, 4. PcG proteins are biochemically associated in two distinct 
multiprotein complexes named Polycomb Repressive Complex (PRC) 1 and 27. The PRC1 
complex includes a large number of subunits with different biochemical proprieties (Ring, 
Chromo and Zinc finger domains)7. The minimal core PRC1 complex for in vitro activities 
requires Polyhomeotic (Ph), Polycomb (Pc), Posterior Sex Comb (PSC), and RING18-10. 
Nevertheless, the great increase in genes redundancy found in mammals suggests the 
existence of different forms of PRC1 that could have cell type specific functions and or 
compensatory effects. Genetic mouse models for some PRC1 subunits support such 
hypothesis. For example, Ring1b-/- (RING1 in flies) mice are embryonic lethal at E9.511 
while Knock Out (KO) mice for the proto-oncogene BMI1 (PSC in flies) are viable but 
present strong developmental defects in the hematopoietic and nervous system12. 
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The core of the PRC2 complex is formed by the three PcG proteins EZH2, EED and 
SUZ12 and by the histone binding proteins RbAp46/4813-16. KO mice for EZH2, EED and 
SUZ12 are embryonic lethal during gastrulation17-19 stressing the developmental role of 
PRC2 also in mammals. Additional subunits of PRC2 include, PHF120, 21, MTF222-24 and 
the DNA binding proteins AEBP213 and JARID222, 23, 25-27.  
The use of high-throughput approaches such as Chromatin Immunoprecipitation (ChIP) 
coupled to microarray hybridization (ChIP-chip) or to next generation sequencing (ChIP-
seq) demonstrated that PcG proteins directly associates to promoters of important regulator 
of cell fate and development1, 28-31. While PcG target genes are highly conserved in 
different organisms (mouse vs. human) the large amount of PcG targets differ between cell 
types1, 32, 33. For example, using a ChIP on chip approach to follow PRC2 activity during 
the differentiation of mouse Embryonic Stem (ES) cells into Neuronal Precursor Cells 
(NPC) and their further terminal differentiation into Neurons, the Dirk Schübeler 
laboratory showed that at each differentiation step, despite a constant number of regulated 
genes, PRC2 exchanged approximately 50% of target genes32. This suggests that the 
downstream pathways are lineage specific and undergo dynamic regulation during 
differentiation. The mechanisms that regulate these processes are still enigmatic and likely 
involve several different factors and signals.  
1.2 Epigenetics: histones and DNA modifications 
Within the cell nucleus, the DNA is tightly associated with histone proteins and form, 
together with other non-histone proteins, hyper condensed structures defined as 
chromatin34. Both histones and DNA present different modifications of which the best 
characterized include histones methylation, acetylation, ubiquitination, and 
phosphorylation as well as cytosine methylation (and its oxidized form) of DNA CpG di-
nucleotides 35. The work of several laboratories have put a tremendous effort to identify 
and characterize the enzymatic activities that catalyze deposition and removal of histones 
and DNA modifications demonstrating that: 1) chromatin modifications play an essential 
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role in regulating DNA transcription and genome stability; 2) Modifications are not stable 
and can be actively reverted by specific enzymatic activities; 3) At least in some cases, 
chromatin modifications are self-sufficient and can be maintained independently of the 
DNA sequence36 linking chromatin modifying factors with epigenetic regulation of 
transcription. 
The term epigenetic was coined by Conrad Waddington in 1942 more than ten years before 
Watson and Crick proposed the structure of the DNA and two years before Oswald Avery, 
Colin MacLeod, and Maclyn McCarty demonstrated that the DNA was the source of 
hereditary information. Waddington defined epigenetic as “a branch of biology that study 
the casual interactions between genes and their products” 37 while a more recent definition 
proposed by Levenson and Sweatt links epigenetic directly to chromatin modifications by 
defining it as: ”the mechanism for the stable maintenance of gene expression that involves 
physically 'marking' DNA or its associated proteins” allowing “ genotypically identical 
cells to be phenotypically distinct” 38. Indeed, several chromatin-modifying factors play 
essential roles in regulating epigenetic phenomena such as gene imprinting and X-
chromosome inactivation39. 
PcG proteins (as well as their counterpart TrxG) belong to this class and execute their 
transcriptional activity by modifying the chromatin surrounding their association sites7, 40. 
The PRC2 complex, through its catalytic subunit EZH2, modifies histone H3 by di- and tri-
methylating (me2/me3) lysine (K) 2713-16. Such activity requires a minimal PRC2 complex 
formed by EZH2, EED and SUZ1219, 41 and it is essential for PRC1 binding to the same 
target sites 42. It has been proposed that the chromo-domain proteins of the PRC1 complex 
(CBX4, CBX6, CBX7 and CBX8) bind H3K27me3 and mediate PRC1 recruitment13, 15, 43. 
PRC1, through the ubiquitin ligase activity of RING1B, mediates ubiquitylation (ubq) of 
histone H2A K119 (in mammals)44 inducing stable transcriptional repression possibly 
thought chromatin compaction and inhibition of SWI/SNF chromatin remodeling activity 8, 
45.  
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1.3 Polycomb group proteins in tumors 
Cancer is a heterogeneous disease that at a molecular level involves a multitude of 
different regulatory pathways and proteins.  In general, at malignant stages, cancer cells 
acquire unlimited replicative potential, angiogenesis capabilities, the ability to evade 
apoptosis, self-sufficiency in growth signals, insensitivity to growth inhibition and acquire 
invasive (metastatic) proprieties46, 47. To achieve this, cells undergo a multistep process 
which gradually leads to a loss of cellular identity towards the acquisition of cancer cell 
capabilities. In both sporadic and hereditary cancers a large number of genetic alterations 
have been characterized and for many of these mutations the oncogenic proprieties were 
validated in mouse models 48-52. Such genetic mutations are required but not fully sufficient 
for cancer development since most cancer models retain latency periods before the onset of 
the disease in order to accumulate additional genetic or epigenetic events to allow full 
cancer development 53. Chromatin-modifying proteins seem to play an important role in 
this process. A classic example is the 11q23 translocation in leukemia involving the Mixed 
Lineage Leukemia gene MLL, a TrxG protein and a histone H3K4 specific 
methyltrasferase 54. Among these factors, PcG proteins have critical roles in the 
development of several cancers 55, 56.  
The first evidence of a PcG protein having a direct role in cancer formation was the 
identification of BMI1 as a proto-oncogene that cooperate with MYC in the formation of 
B-cell Lymphomas 57. Since then, the attention at role of PcG proteins in human cancer 
gradually increased and raised dramatically together with the discovery of the enzymatic 
activities of both PRC1 and PRC2 complexes13-16, 44.  
Together with BMI1, the best-characterized PcG protein in human cancer is the catalytic 
subunit of the PRC2 complex EZH2. Ten years later the discovery of BMI1 oncogenic 
proprieties, EZH2 was identified as a direct downstream target of the pRB/E2F pathway 
and one of the most frequent over-expressed genes in malignant prostate cancer 58, 59. 
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Despite several subunits of both PRC1 and PRC2 complexes have critical roles in 
regulating PRCs activities, the cancer related attention of the scientific community mainly 
focused on BMI1 and EZH2. Whether this is a bias or a consequence of unproductive 
results is unclear. Some contradicting results on other PRC1 components suggest that PcG 
oncogenic proprieties might reside in single subunits rather than complexes activities. In 
addition few Polycomb proteins have been proposed as tumor suppressor in specific 
tumour types60-62. This unexpected and less known face of PcG proteins is in contradiction 
with the extensively characterized oncogenic role of PcGs. This intriguing observation may 
find an explanation in uncharacterized functions of PcG proteins that remain to be 
investigated. 
1.4 Polycomb in Prostate Cancer 
EZH2 was identified as one of the most frequent and highly expressed gene in malignant 
prostate cancers 58. High EZH2 expression strongly correlates with metastatic tumors and 
poor survival making EZH2 a potential marker for prostate cancer prognosis 58. Like 
EZH2, also BMI1, RING1B and CBX7 63, 64 are found highly expressed in prostate tumors. 
Using RNAi and ectopic expression approaches, different studies have characterized the 
role of PcGs in the proliferation of prostate cancer cells. EZH2 RNAi in different cell lines 
demonstrates its essential role in cancer cell proliferation 58, 64-66. Similar effects were also 
reported for CBX7 63. Importantly, overexpression of both EZH2 and CBX7 promote cell 
proliferation and transformation of benign cells 58, 63, 67. Interestingly, despite CBX7 
expression only give a slight proliferative advantage to LNCaP cells (androgen-sensitive 
human prostate adenocarcinoma cells), it cooperates with C-MYC to promote insensitivity 
to androgen dependent growth inhibition 63.  In contrast, the expression of MEL18 (the 
mammalian paralog of BMI1) is frequently lost in prostate tumors suggesting a tumor 
suppressive function 68. It is not clear if loss of MEL18 expression has any causative role in 
prostate cancer but this observation could odd with the redundant roles of MEL18 and 
BMI1 in regulating normal hematopoiesis and INK4A-ARF expression 69-71. In addition 
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Bmi1 and Akt pathways are found potentiated in high grade prostate tumors and Bmi1 
phosphorylation by Akt enhanced its E3 ligase activity and, it’s supposed, also its 
oncogenic ability in an Ink4a/Arf independent, DNA damage repair dependent manner72. 
The mechanisms that contribute to PcG over-expression in prostate cancer are still poorly 
understood. The frequent deregulation of the pRB/E2F pathway likely contributes to PcG 
overexpression 59. Specific amplifications of both the EZH2 and BMI1 loci correlate with 
high protein expression 73, 74. In addition, loss of expression of the micro RNA (miR) 101 
in metastatic prostate tumors correlates with high EZH2 expression 75. In this work, the 
authors showed that in breast and prostate cancer cells miR-101 targets EZH2 mRNA and 
negatively regulates its translation 75. 
The mechanisms by which PcG proteins could promote prostate cancer development are 
also still poorly understood. Growth inhibition induced by CBX7 RNAi correlates with 
increased ARF and p16 expression 63. Other evidences have been presented on a direct role 
of EZH2 in repressing PSP94, a small protein abundantly secreted by the prostatic gland 
that inhibit tumor growth and metastases whose expression is silenced in prostate cancers 
76. In addition, an extensive worked aimed to identify genes directly regulated by EZH2 
found ADRB2 as an important EZH2 target 66. ADRB2 is a ß-adrenerigic receptor whose 
expression is directly silenced by EZH2 in metastatic prostate cancers. Loss of ARDB2 
expression induce cell invasion in benign prostate cells while its constitutive expression 
counteract the proliferative and metastatic proprieties induced by EZH2 overexpression. 
Such regulatory pathway is not restricted to prostate cells and is conserved in a model of 
mammary epithelial cell transformation 66. An additional target of polycomb repression is 
the Ras GTPase-activating protein DAB2IP linking PcGs to RAS signaling pathway 77. 
Finally, a study aimed to identify PcG regulated genes in prostate tumors identified a 
signature of 14 PcG direct targets that, when silenced, predicts poor patients survival 78. 
Despite the prognostic relevance of this finding, the link between repression of these 
targets and cancer development has not been investigated. Moreover it has also been 
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shown that in prostate cancer cells Ezh2 represses a complex miRNA network whom  
would, if de-repressed or ectopically express, target members of PRC1 leading to their 
silencing and loss of oncogenic potential79. More recently it has been proposed that Ezh2 
can regulate tumorigenicity of castration-resistant prostate cancer cells in a “solo” mode. 
This consists in its ability to promote tumors in a PRC2 independent manner acting as 
transcriptional co-activator for different transcription factors included the androgen 
receptor80, 81. Finally, for correctness sake, it must be said that this last observation odds 
with previous published data showing genome wide repression of target genes impressed 
by androgen receptor through Ezh2 binding82. 
1.5 Polycomb in Brain Tumors 
Glioblastomas are aggressive tumors arising from all cells of the central nervous system. 
Glioblastomas are highly proliferative with a poor prognosis that results in rapid death 
within 12 months from diagnosis 83. Several publications reported that BMI1 and EZH2 are 
highly expressed in Glioblastomas 84-87. Down-regulation of either EZH2 or BMI1 
expression blocked glioblastoma cell proliferation 84, 87. RNAi mediated down regulation 
of EZH2 reduced tumor formation in vivo consistent with the block of cancer development 
observed in mice treated with the EZH2 inhibitor DZNep 86, 87. Importantly, using Bmi1-/- 
mice, the Maarten van Lohuizen laboratory showed that Bmi1 is essential for the 
development of glioblastomas in a mouse model that involves loss of Ink4A-Arf 
expression and Egfr mutations 88. Interestingly, the requirement of Bmi1 in such model 
highlights Ink4a/Arf independent functions of Bmi1. In glioblastomas, loss of miR-128 
expression negatively correlates with Bmi1 levels. Mir-128 directly regulates Bmi1 
translation suggesting an important regulatory mechanism for PcG overexpression in brain 
tumors 85.  
The downstream effects to BMI1 over expression are still poorly characterized. BMI1 acts 
positively on GSK3ß activity, a growth promoting kinase highly expressed in 
glioblastomas 86. Another report proposed a role for Bmi1 in regulating p21 expression to 
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allow neural stem cells (nSC) self-renewal suggesting a potential mechanism to suppress 
anti-proliferative factors independently of Ink4a/Arf89. In addition, it was proposed that 
BMI1 overexpression is directly regulated by N-MYC and that BMI1 controls the 
expression of KIF1ß and TSLC1, two potential tumor suppressor genes in neuroblastoma 
90. Moreover, loss of Bmi1 in Ink4a/Arf null nSC, leads to an increased secretion of 
extracellular matrix and increased adhesion trough the ß1-integrin receptor suggesting that 
Bmi1 overexpression could induce low matrix production and adhesion favouring motility 
and invasion 91. No reports have been presented for other PcG proteins with the exception 
of an overlapping function of MEL18 with BMI1 in odds with its putative tumor 
suppressive role in prostate cancer 92. The possible existence of PRC2 and PRC1 non-
histone targets is now a new unexplored fascinating field. This was partially shocked by 
the recent work from Jürg Muller lab that elegantly showed, in D. Melanogaster, how 
replacement of all histones H3 with H3K27R mutants recapitulate PcG null phenotype in 
flies, strongly suggesting that, at least in Drosophila, PcGs activity goes entirely through 
its ability to methylate Lysine 27 on histone H393. Nonetheless recently STAT3 has been 
reported as a PRC2 non-histone substrate in glioblastoma stem-like cells. Ezh2 
phosphorylation on serine 21 is required for STAT3 methylation, this methylation in turn 
enhances STAT3 activity by means of tyrosine phosphorylation increasing its oncogenic 
ability in glioblastoma cells94. Finally a study that combined an RNAi screening with 
ChIP-seq data revealed an Ink4/Arf independent role for Bmi1 in maintaining malignant 
glioma-stem cells probably indirectly negatively acting on Atf3 tumor suppressor 
pathway95. Moreover in contrast to its already described oncogenic role, in that study, 
CBX7 has been reported to act as tumor suppressor95 adding another layer of complexity to 
the already complicated PcG-cancer tale. Anyway a tale is never complex enough if there 
is not at least another point of view from which the reader could be intrigued, and in this 
case “the other point of view” consists in the histone tail mutations reported in pediatric 
gliomas96, 97. These mutations have been identified in pediatric glioblastoma by two 
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different groups that showed the presence of a couple of somatic point mutations on the 
histone genes H3F3A and HIST1H3B causing a lysine to methionine substitution at 
position 27 (K27M) or a glycine to arginine substitution at position 34 (G34R) in a large 
number of patient98-100. Despite the K27M seems to occur only in one or two of the several 
histone H3 alleles therefore, most likely, not accounting for an important representation in 
the chromatin landscape, a couple of very recent works ruled out that, this is sufficient to 
globally affect the PRC2 activity101, 102. Both these works demonstrated indeed that the 
entire ability of PRC2 to tri- or di- methylate the histone H3 on the lysine 27 was 
completely abolished in pediatric glioma derived cells presenting the K27M mutation101, 
102. Moreover, exogenous expression of H3K27M definitely impairs PRC2 activity also in 
other cell types suggesting a cell type-independent mechanism of action for this mutant 
histone101, 102. Finally, one of the two works strongly suggests, using biochemical 
approaches, that this mutant can inhibit PRC2 activity by tightly binding to Ezh2 catalytic 
pocket inhibiting its function101. Interestingly enough, from that study emerged that by 
exogenous expression of the mutant histone in 293T cells, this was found in only the 1% of 
the chromatin but at the same time inhibits the entire PRC2 catalytic activity thus strongly 
suggesting its possible in trans activity on Ezh2101. In conclusion, despite in one hand PcG 
proteins seem to be pro-oncogenic in glioblastomas, on the other a large fraction of 
pediatric gliomas presents a mutation on histone H3 that is able to entirely inhibit PRC2 
function. Even if the role of the mutated histone in pediatric glioma pathogenesis remains 
still to be established, its discovery along with its mechanism of action are largely 
irreconcilable with the well-characterized pro-tumorigenic activity of PcG proteins, 
contributing to add another mysterious piece to the already complicated puzzling PcG-
cancer tale. 
1.6 Polycomb in Breast Cancer 
Breast tumors are another well-documented cancer type where PcG proteins are found 
significantly overexpressed. EZH2 is highly expressed in a wide range of breast cancers 59, 
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103, 104. Its high expression is detected in pre-neoplastic mammary lesions suggesting that 
deregulated PRC2 activity is an early event in the development of breast tumors 105. 
Similar to prostate cancer, high EZH2 expression correlates with metastatic sporadic and 
familial breast tumors and strongly associates with bad prognosis 104, 105. Analysis of 
BMI1, MEL18 and HPC2 showed that only BMI1, between the PRC1 group, is found 
overexpressed in breast cancers correlating with MYC expression 106. MEL18 expression 
was instead frequently lost further supporting its tumor suppressive role in epithelial 
tumors 107. Both BMI1 and EZH2 show direct oncogenic roles in breast cancer formation. 
EZH2 overexpression in normal immortalized epithelial cells induces anchorage 
independent growth and invasive potential 104 while BMI1 overexpression collaborates 
with H-RAS in transforming MCF10A breast epithelial cells 108. One report proposed that 
EZH2 is essential for the proliferation of BRCA1-/- cells and those similar phenotypes are 
observed with the use of the EZH2 inhibitor DZNep 109. In vivo overexpression of EZH2 is 
not sufficient to induce breast cancer formation yet induce full penetrant hyperplasia of the 
mammary epithelia supporting in vivo EZH2 oncogenic functions 110. In addition to 
ADRB2 repression 66, no other mechanisms have been proposed in breast cancer. In vivo 
over-expression of EZH2 induces an upregulation of the Wnt/ß-Catenin signaling pathway 
and association of EZH2 with nuclear ß-Catenin 110. Despite the attractive transcriptional 
link, no mechanisms have been proposed for such interaction. Importantly, poorly 
differentiated breast tumors present an ES cell like signature characterized by the 
expression of pluripotency factor like NANOG, OCT4, SOX2 and MYC and PcG targets 
repression. Such signature strongly correlates with high-grade Estrogen Receptor negative 
tumors and poor clinical outcome 111. Finally, an exciting publication demonstrated that 
HOTAIR, a Large intervening non coding (Linc) RNA, is overexpressed in primary and 
metastatic breast tumors and that HOTAIR overexpression associates with a poor clinical 
outcome 112. HOTAIR is transcribed from the HOXC locus and through direct association 
with the PRC2 complex regulates HOXD expression in normal skin fibroblasts 113. Direct 
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HOTAIR overexpression increases cancer epithelial cells invasiveness in a PRC2 
dependent manner while loss of HOTAIR expression reduced this potential 112. Consistent 
with its ability to bind the PRC2 complex, HOTAIR overexpression redirect PRC2 binding 
to the DNA towards a fibroblast like signature 112. More recently it has been shown that 
BRCA1, a well-known TSG in breast and ovarian cancer, is able to inhibit PRC2 binding 
to HOTAIR thus resulting in de-localization of EZH2 on chromatin114. Such result not only 
introduces a new key mechanism of regulation of PcG functions in cancer cells but propose 
an important role for LincRNAs in epigenome regulation.  
1.7 Polycomb in Hematological Malignancies 
As mention earlier, BMI1 was first identified as a proto-oncogene that collaborates with c-
Myc in inducing B-Cell Lymphomas57. EZH2, EED and BMI1 have important functions in 
normal B-cell development and KO mouse models for these proteins display impairment in 
proper B-cell differentiation12, 115, 116. EZH2 and BMI1 are frequently expressed at high 
level in different types of B-cell lymphomas117-120. BMI1 over-expression correlates with 
an active B cell phenotype121 and transgenic mice expressing BMI1 in the lymphoid 
compartment stimulate lymphoma formation122. Even though, historically, BMI1 has been 
largely studied in lymphoma and hematological malignancies, today, indisputably, the 
scientific world eye is tightly focused on EZH2. This is largely due to the discovery of 
recurrent mutations identified in diffused large B-cell lymphomas (DLBCL) that affect 
EZH2 SET catalytic domain. Initially, a frequent (~7 to 20% of cases) mutation at 
Tyrosine (T) 641 of EZH2 in B-Cell Lymphomas that, at that time, was considered an 
inactivating mutation123. That interpretation, indeed,  was in sharp contrast with the general 
idea that increased PRC2 activity had oncogenic functions. Moreover that mutation was 
found only in heterozygosity indicating that a wild type EZH2 allele is required for 
lymphoma maintenance123. At that time the information were very few and poorly 
characterized to really rule out how an EZH2 heterozygote putatively inactivating mutation 
could affect lymphomagenesis and the overall PRC2 activity. During  the same year, a 
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biochemical study identified the T641 mutations (T641F, T641N and T641S)  has a 
“super-activating” mutation124. That work demonstrated, indeed, how the mutated EZH2 
was able to rapidly and processively convert H3K27 di-methylation to H3K27 tri-
methylated H3K27 while less efficiently converts mono-methylation to di-methylated 
H3K27 and shows nearly no activity on unmethylated histone H3 compared to EZH2 wt 
containing PRC2124. These findings were also successively confirmed by another similar 
work125. Therefore, while initially this mutation was erroneously considered inactivating, 
EZH2 T641 mutations are, on the contrary, increasing the normal EZH2 ability to convert 
H3K27me2 to H3K27me3. Whether this mutation participated or not to lymphomagenesis 
is still not fully understood. However, different labs and companies have made strong 
efforts to develop selective compounds which are able to inhibit the mutated form of 
EZH2126. When lymphoma cells were treated with those compounds, the tumorogenic 
potential was abolished or strongly impaired both in vitro and in vivo, thus strongly 
supporting a pivotal role for mutated EZH2 in the lymphoma pathogenesis127-129. However, 
the inability of the mutated form to efficiently methylate the unmethylated histone H3 or to 
convert H3K27me1 to H3K27me2/me3 highlights the key role for EZH2 wild-type 
allele124. This mechanism is supported by the lack of homozygous mutations in DLBL 
derived cells130. Indeed, a transgenic mouse carrying an inducible extra copy of the EZH2 
allele that harbours the T641N missense mutation was recently generated131. When the 
mutated allele was expressed in the germinal center B-cells, it led to a strong germinal 
center hyperplasia suggested to be largely caused by the transcriptional repression of the 
Cdkn1a tumor suppressor locus and by an impairment of differentiation131. However, the 
mutant Ezh2 expression in the germinal center was never compared with its WT 
counterpart, leaving open the possibility that is the mere EZH2 overexpression to induce 
hyperplasia. Importantly, a mouse model harbouring an inducible Ezh2 extra allele in the 
hematopoietic cells was already available132 and activation of the extra-copy of Ezh2 wild-
type allele in hematopoietic cells was shown to induce myeloproliferative diseases132.  An 
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additional PcG protein involved in Lymphoma development is CBX7. CBX7 is a PRC1 
chromo-domain subunit that mediates PRC1-H3K27me3 interaction 43. CBX7 is expressed 
in germinal center lymphocytes and in germinal center derived lymphomas in correlation 
with Myc expression.  Ectopic expression of CBX7 in lymphoid progenitors initiates T-cell 
lymphomas and its co-expression with Myc induces formation of aggressive B-Cell 
lymphomas 133. Both PRC2 and PRC1 complexes play an important role in the oncogenic 
activities of PML-RARα and PLZF-RARα, two fusion proteins that cause Acute 
Promyelocytic Leukemia 134. Both fusion proteins induce recruitment of PRCs repressive 
activities at retinoic acid responsive promoters and depletion of either EZH2 or BMI1 
decrease the oncogenic potential of PML-RARα 135 and PLZF-RARα 136 by promoting 
cellular differentiation. In addition, BMI1 is found frequently over-expressed in patients 
with either Acute Myeloid Leukemia or Chronic Myeloid Leukemia 137-139. In the latter 
case, high BMI1 expression correlates with bad survival 138. Loss of BMI1 in mice delay 
the development of primary leukemia and, importantly, it prevents the onset of secondary 
leukemia possibly by promoting cancer stem cells exhaustion 140. Interestingly, the use of 
PRC2 inhibitors such as DNZep reduces the leukemic potential of HL60 cells 141. In line 
with the different roles of PRC1 members in solid tumors, the expression of PHC1/RAE28, 
a member of the PRC1 complex, is lost in some patients with Acute Lymphoid Leukemia 
suggesting a putative tumor suppressive role 142. Finally, two works discovered that the 
EZH2 locus is frequently targeted by deletions, missense and frame-shift mutations in 
myeloid disorders 130, 143. In few cases such mutations are homozygous resulting in global 
loss of EZH2 enzymatic activity 130. Finally, the global hematopoietic genetic knockout of 
Ezh2 in mice, paradoxically, results in a highly-frequent γδ T-cell acute lymphoid 
leukemia (T-ALL)62 in sharp contrast with the myeloproliferative disorders reported when 
Ezh2 was overexpressed in the same cells132.  
1.8 Polycomb in other tumors 
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Implications for EZH2 and BMI1 have been proposed in the development of lung tumours. 
EZH2 expression is low in normal epithelia but is found highly expressed in Squamous 
Lung Cell Carcinomas (SLCC) and correlates with high BMI1 and Ki67 expression144. 
Like EZH2, BMI1 is frequently overexpressed in SLCC (77% of cases)145. Consistent with 
this, in non-Small Cell Lung Cancer, BMI1 is required in vivo for K-RAS induced 
tumorigenesis with a mechanism that links RAS mutation lung cancer sensitivity with PcG 
proteins ability to repress the INK4b-ARF-INK4a locus (discussed later) 146. Interestingly, 
the exposure of lung carcinoma cell lines to tobacco smokes condensate (TSC) represses 
the expression of the WNT signaling antagonist DKK1. DKK1 expression is frequently 
lost in tumor samples and knock down of DKK1 enhance tumor formation similar to TSC 
exposure. Importantly, TSC exposure triggers PcG proteins recruitment at the DKK1 
promoter suggesting that TSC can induces epigenetic reorganizations that favor cancer 
formation through PcG mediated repression of tumor suppressor genes 147. Significant 
increases in EZH2 and BMI1 expression has been reported in several others tumors 
suggesting that deregulation of PcG activities is a common feature of transformed cells. 
This includes, Hepatocellular Carcinomas148, 149, Oral Squamous Cell Carcinomas150, 151, 
gastrointestinal cancers152-155, ostosarcomas156 and bladder tumors157-160. In melanoma, 
while EZH2 expression increases between benign to melanoma nevi161, BMI1 expression 
is lost in aggressive tumors and its high expression correlates with a favorable outcome 
suggesting a tumor-suppressive role162. In contrast, in normal nasopharyngeal epithelial 
cells, BMI1 over-expression induces epithelial to mesenchymal transition through a 
mechanism that involves direct repression of PTEN expression163. In bladder tumors, 
EZH2 levels are controlled by mir-101 similar to mammary and prostate cells 164. High 
EZH2 expression in bladder cancers correlates with repression of the pro-apoptotic protein 
APAF1 and is associated with tumor stage and invasive potential 165. In pancreatic 
carcinomas, BMI1 expression is frequently increased with particular high levels in cancer 
stem cells 155. Recently it has been shown that Ezh2 is required for pancreatic cells 
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proliferation during pancreatic regeneration post-injury166. The mechanism through which 
Ezh2 controls pancreatic regeneration involves its ability to repress the Ink4a/Arf locus, 
moreover loss of Ezh2, paradoxically, seems to accelerate K-RAS driven pancreatic 
tumor166. In contrast, CBX7 expression is lost with high frequency in pancreatic 
carcinomas suggesting opposite functions for BMI1 and CBX7 in these tumors167.  
Consistent with this , a genomic region containing the PHC3 locus undergoes frequent loss 
of heterozygosity in osteosarcomas 168. PHC3 expression is lost in approximately 65% of 
tumor samples of which a large proportion contains PHC3 mutations. The putative tumor 
suppressive function of PHC3 (as well as for other PRC1 proteins) is not clear but in 
quiescent and differentiated cells PHC3 co-localizes and associates with E2F6 suggesting 
anti-proliferative proprieties 168.  Finally, in Endometrial Stromal Sarcomas (ESS), the 
genomic loci of two different PcG proteins (SUZ12, and PHF1) translocate with the JAZF1 
locus 169, 170. These translocations are found with high frequency in ESS leading to the 
expression of poorly characterized fusion proteins. Is not clear if the expression of these 
fusion proteins has oncogenic functions but an mRNA transcript, identical to the JAZF1-
SUZ12 fusion, is expressed as a product of a transplicing event in normal endometrial cells 
171. Such transpliced mRNA is specifically expressed in the proliferative stage of stoma 
cells during the menstrual cycle suggesting that JAZF1-SUZ12 fusion have growth 
promoting effects that are transiently required in the normal endometrium. Constitutive 
expression, due to genes translocation, might instead have oncogenic effects. 
1.9 Polycomb recruiting mechanisms 
The mechanisms of PcG recruitment to specific DNA sites are still poorly understood. 
Genome wide studies have shown that PcG proteins bind preferentially CG rich genomic 
regions but sequence analysis and transcription factor binding sites predictions failed to 
identify enriched consensus sequences1. In Drosophila, several DNA binding transcription 
factors are required for PcG and TrxG association at Polycomb Responsive Elements 
(PREs)172, this allowed the development of an algorithm to determine novel PREs showing 
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that some predicted elements have PRE proprieties in vivo173. Despite this, the use of 
genome wide ChIP-chip approaches showed that predicted elements and PcG binding sites 
poorly overlap174. Moreover, application of such algorithm to mammalians genome fails to 
predict any potential PRE173 consistent with the poor conservation of the Drosophila DNA 
binding factors in mammalian cells. In contrast, recent reports have identified two 
mammalian genomic regions with putative PRE behavior175, 176 supporting a mechanistic 
conservation between flies and mammals. PcG and TrxG proteins seem to compete in 
metazoan for the same regulatory pathways (binding sites) and, despite the mechanisms of 
recruitment are poorly understood, deregulation of such equilibrium by either loss or gain 
of function of specific subunits may reflect in changes in cell identity that could play 
essential roles in pathogenesis. In mammalian cells, the DNA binding factors Aebp213, 
Jarid1A 22, 27, 177 and Jarid2 22, 23, 25-27 associates with the PRC2 complex. These factors are 
required for the repression of specific PRC2 target genes but only Jarid2 is required for 
genome-wide PRC2 localization at chromatin in mouse ES cells26. Despite Jarid2 
interaction to PRC2 is not restricted to ES cells, the differences in target genes between 
cell types suggests tissue specific mechanisms of PcG recruitment1, 32, 33. Therefore it is 
possible that Jarid2 stabilizes PRC2 association with DNA but that combinations with cell 
type specific transcription factors might specify target genes association. For example, 
SNAIL1 recruits PRC2 to repress E-CADHERIN expression 178 suggesting a potential role 
of PRC2 in regulating important cell adhesion molecules that inhibit Epithelial to 
Mesenchymal Transition (EMT) of metastatic cells. Consistent with this, PRC2 was also 
reported to interact in breast cancer cells with two critical EMT players, Estrogen Receptor 
and ß-CATENIN 179. Several reports have recently shown that PRC complexes interact in 
the nucleus with non-coding (nc) RNAs. A possibility is that tissue specific ncRNAs 
determines and or contribute to PcG targets specification and that deregulations of such 
activities might have important roles in cancer development. So far the PRC2 complex was 
shown to interact with Xist, Tsix RepA, (ncRNAs of the X-chromosome inactivating 
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machinery) and HOTAIR. RepA mediates PRC2 recruitment to the inactivating X-
chromosome (Xi) 180 while HOTAIR is required for PcG association and HOXD locus 
repression in primary foreskin fibroblasts 113. In both cases, RNAi mediated inhibition of 
RepA and HOTAIR results in defective PcG recruitment. In addition to PRC2, CBX7 was 
shown to interact with ANRIL, a non-coding antisense transcript of the INK4B-ARF-
INK4A  locus 181. Such interaction plays an important role in PcG association at the INK4A 
locus that; together with the high levels of ANRIL expression in prostate cancer, identifies 
a new important component of INK4A-ARF repression in cancer cells. A similar 
mechanism has been presented for HOTAIR in breast cancer where high HOTAIR 
expression correlates with an epigenetic reprogramming of PcG binding sites. Importantly, 
HOTAIR over-expression confers tumorigenic potential to benign cells in a PcG dependent 
manner112. It is still not clear how ncRNAs could regulate PcG binding but a recent report 
showed that HOTAIR can function as a scaffold for simultaneous recruitment of co-
repressor complexes182. However, only very recently it has been shown that PRC2 can bind 
RNA in a promiscuous manner thus challenging the current specific ncRNA mediated 
PRC2 recruitment183. For what concerns PRC1 recruitment, for years the general accepted 
model consisted in a PRC2 dependent recruitment mechanism184. Precisely it has been 
shown that stable components of PRC1 such as the CBX proteins can target the entire 
PRC1 directly to chromatin through theirs ability to bind the H3K27me3 mark13, 185. 
Indeed it has been demonstrated that the abrogation of the entire H3K27me3 in Eed null 
mouse ES cells affects global Ring1b stability at chromatin but this does not affect the  
histone H2A lysine 119 mono-ubiquitination (H2a K119ub) levels186. These data indicate 
that, although PRC2 activity is required to stably localize the PRC1 at chromatin, 
H3K27me3 is generally indispensable to maintain global H2a K119ub levels. Moreover, 
very recently, different PRC2-independent PRC1 chromatin recruitment have been 
proposed186-189 that could explain how global H2a K119ub levels do not change in PRC2 
knockout cells. 
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1.10 Polycomb inhibitors 
Due to the frequent deregulation of PcG activities in cancer cells and their role in 
regulating their proliferative potential, the inhibition of PcG functions is an attractive 
strategy for therapeutic approaches126, 190. To date no inhibitors have been developed for 
PRC1 while the 3-Deazaadenosine analog 3-Deazaneplanocin A (DZNep) has been shown 
to inhibit EZH2 activity191. 3-Deazaadenosine inhibits S-adenosylhomocysteine (AdoHcy) 
hydrolases and, by increasing AdoHcy intracellular levels, globally inhibits 
methyltransferases. DNZep treatment induces a strong degradation of EZH2 leading to loss 
of H3K27me3. DNZep treatment of cancer cells blocks proliferation induces apoptosis and 
reactivates PRC2 target genes expression109, 141, 191, 192. However, some concerns were 
raised about DNZep specificity and different reports have shown a more general effect of 
DNZep in inhibiting several other histone lysine and arginine methylations191, 193. 
Moreover, inhibition of EZH2 activity was reported by treating breast and bladder cancer 
cells with adenosine dialdehyde, another analog of 3-Deazaadenosine, and with the 
inhibitor of methyltransferases Sinefungin, an analog of S-adenosyl-methionine 193. 
Whether or not these drugs are more specific then DNZep remains unclear. Recently new 
specific drugs targeting Ezh2 catalytic pocket have been generated127-129, 131, these aimed 
preferentially to inhibit the new EZH2 gain-of-function mutations found in lymphoma 
(discussed earlier) but some of them could be also used to inhibit the wild type form of 
EZH2. An additional possibility to target PcG functions might reside in the ability of PRC1 
and PRC2 complexes to bind directly H3K27me3 36, 194. While PRC1 affinity for 
H3K27me3 is weak and rather unspecific, PRC2 seems to have much stronger affinity and 
higher specificity 36. It has been proposed that PRC2 binding to H3K27me3 is important 
for the maintenance of H3K27me3 during DNA replication 36. H3K27me3 is directly 
bound by EED through its WD40 domain 194. Importantly, mutations of critical EED 
H3K27me3 binding residues demonstrate that the association of PRC2 to H3K27me3 is 
essential to rescue both the developmental phenotypes and the global loss of H3K27me3 
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observed in EED deficient flies 194. Inhibiting molecules specific for the aromatic methyl 
lysine-binding cage of EED may serve as an alternative strategy to block PRC2 functions. 
Only very recently Orkin’s lab generated a molecule that is able to uncouple Ezh2:Eed 
binding thus inhibiting Ezh2 catalytic activity and stability195. 
1.11 Ink4b-Arf-InK4a locus and Polycomb control 
One of the best-characterized PcG target in mammalian cells is the INK4b-ARF-INK4a 
locus 196-198. This locus codifies for p15INK4b, p19ARF (p14ARF in humans) and p16INK4a, 
three important negative regulator of cell cycle that play important oncosuppressive roles 
in human tumors 199. While p16INK4a and p15INK4b binds to Cyclin/CDK complexes and 
inhibit cell cycle by blocking CDK mediated phosphorylation of the Retinoblastoma 
protein pRB, p14ARF binds to MDM2 and blocks its ability to degrade p53. Stabilization of 
p53 has anti-proliferative and pro-apoptotic effects in part through the transcriptional 
activation of the Cyclin/CDK inhibitor p21 199. Loss of function of any of these proteins 
has growth-promoting effects and prevents cells to undergo replicative and or oxidative 
induced senescence 199. In proliferating cells, PcG proteins associate to the INK4b-ARF-
INK4a locus to maintain its repression. Both PRC1 and PRC2 components associate 
specifically at the p16INK4a promoter 196, 197. Several reports have shown that loss of PcG 
functions induce cellular senescence and correlates with activation of INK4b-ARF-INK4a 
expression 196-198, 200. BMI-1deficient mouse embryonic fibroblasts (MEF) undergo a 
dramatic block of proliferation and a strong activation of p15INK4b, p19ARF and p16INK4a 198. 
Consistent with this, BMI1 cooperates with C-MYC in lymphomagenesis by repressing 
INK4b-ARF-INK4a thus decreasing C-MYC induced apoptosis 201. Similar to BMI1, other 
PRC1 subunits such as CBX7, CBX8 and MEL18 as well as PRC2 subunits like EZH2 
have been implicated in INK4A-ARF regulation Forced expression of CBX7, CBX8 and 
EZH2 allows escaping senescence in mouse and human primary cells 59, 196, 197, 200 while 
loss of function of CBX7, CBX8, MEL18, EZH2 and SUZ12 induce premature senescence 
in mouse and human cells 19, 59, 69, 197, 200. However, MEF derived from Cbx7 null mice 
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showed growth rate comparable to wild-type MEF202. The physiological relevance for such 
regulation has been demonstrated in different genetic mouse models. For example, the 
developmental defects of Bmi1-/- mice can be partially rescued by Ink4a-Arf 
inactivation203 while the embryonic lethality of Ring1b-/- mice can be rescued from E9.5 to 
E11.511. Inactivation of Ink4a-Arf fully rescues the development of diabetes mellitus 
induced by ß-cells specific inactivation of Ezh2 204. On the same line Bmi1 controls ß-cells 
proliferation during their regeneration ad aging counteracting MLL1 recruitment and 
activation of Ink4a/p16 transcription205. Moreover, very recently, it has been demonstrated 
that a combination of trithorax depletion and ectopic Ezh2 expression in β-pancreatic cells 
leads to rejuvenation of those cells by means of transcriptional repression of the Ink4a/Arf 
locus206. In addition, conditional Ezh2 depletion in proliferating epidermis progenitors 
induce skin defects with premature differentiation of basal layer cells that correlate with a 
strong activation of Ink4b-Arf-Ink4a expression207. Ezh1, the Ezh2 homolog, depletion in 
mouse hematopoietic stem cells (mHSCs) impairs their self-renewal and proliferation 
potential, these defects can be completely reverted by the concomitantly deletion of the 
Ink4a/Arf locus208. In rodent incisor stem cells, Bmi1 ensure their proliferation by 
repressing the Ink4/Arf locus and the Hox genes209. Such results stress the importance of 
Ink4a-Arf repression but also suggest Ink4a-Arf independent functions for PcG proteins. In 
support to this, thymocytes differentiation and growth defects of Bmi1 KO mice can be 
rescue by genetic inactivation of a downstream kinase of the DNA damage response, Chk2 
210. Such phenotype has been attributed to a Bmi1 dependent deregulation of mitochondrial 
functions that leads to aberrant production of free radicals triggering a DNA damage 
response. Ink4a/Arf loss cannot rescue such defects and Chk2 KO mediated rescue of Bmi1 
phenotypes occurs independently of Ink4a-Arf repression210. In line with these findings, 
there is not a clear correlation between overexpression of PcG proteins and INK4b-ARF-
INK4a repression in human tumors. For example, no correlation between BMI1 and 
p16INK4a expression was found in different hematological malignancies121, while a negative 
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correlation between BMI1, p16INK4a and p14ARF was reported in non-small cell lung 
cancers211. In contrast, half of BMI1 positive Hodgkin lymphomas had a positive 
correlation with p16INK4a expression 212. Importantly, in a mouse model of EGFR-driven 
glioma, Bmi1 is essential for in vivo tumor formation independently of Ink4-Arf88. 
Moreover, hepatocellular carcinomas and transformation of MCF10A mammary epithelial 
cells by co-expression of RAS and BMI1 have no effect on Ink4a-Arf expression 108 while 
in a lung cancer mouse model BMI1 play a role in repressing the INK4A-ARF locus during 
K-RASG12D driven transformation213.  In Oral Squamous Cell Carcinoma, BMI1 is 
essential for cancer cell proliferation independently of INK4A-ARF 150 and the oncogenic 
effects of BMI1 in an Ewing Sarcoma’s tissue culture model show no dependency on 
INK4A-ARF expression214. All together these evidences demonstrate the importance of 
PcG mediated INK4A-ARF repression but also highlight the existence of additional 
regulatory pathways that play essential roles in development and carcinogenesis. 
1.12 Preface 
Uncontrolled proliferation is one of the hallmarks of cancer that is required for tumour 
growth and spreading 215. The normal cell cycle progression is tightly controlled by a 
variety of molecular checkpoints that supervise the biological processes that take place in 
the different phases of the cell cycle 216.  Notably, the cell cycle checkpoint that involves 
the Ink4a/Arf-p53-pRb axis has been regarded and described as the principle barrier for the 
initiation and maintenance of neoplastic transformation217-220. The cross talk among the 
proteins active in these pathways and the epigenetic control of Ink4a/Arf expression has 
been largely investigated to characterize the role of proto-oncogenes that negatively affect 
this molecular checkpoint221, 222. Among these, PcGs exert a fundamental role in 
controlling Ink4a/Arf transcriptional repression to promote cell cycle progression in 
physiological and pathological conditions199. PcGs pro-proliferative and oncogenic activity 
have been tightly linked with the transcriptional control of this locus, suggesting that PcG-
dependent control of proliferation mainly depends on the ability to repress Ink4a/Arf 
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expression 72, 133, 166, 196-198, 200, 201, 203-205, 223-225. Moreover, the PcG proteins Ring1b and 
Bmi1 can also directly regulate the stability of p53, further stressing their role in regulating 
cellular proliferation and tumorigenesis by negatively acting on the pRb-p53 pathway226-
228. In contrast, few studies have also highlighted that the proto-oncogene Bmi1 can control 
proliferation independently of Ink4a/Arf expression88, 214, 229. Although the overall role of 
PRC1 and PRC2 activities remains completely uncharacterized, this finding suggests the 
existence of additional mechanisms by which PcGs can regulate cellular proliferation. 
Several components of PRC1 and PRC2 are frequently overexpressed in human tumours 
correlating with negative prognosis and poor survival 56. Considering that the majority of 
tumours are also characterized by mutations in the Ink4a/Arf-p53-pRb axis 230, we 
speculate that PcGs can control cellular proliferation through additional mechanisms that 
acquire a particular significance during oncogenesis and represent a potential therapeutic 
value127-129.  
 
CHAPTER 2: Results 
 
2.1 PcG proteins are required for fibroblast proliferation at low oxygen tension 
To study the relationship between PcG proteins and cell-cycle checkpoints in regulating 
cellular proliferation, we analysed the role of PRC1 and PRC2 activity in the proliferation 
of mouse embryonic fibroblasts (MEFs) grown at low oxygen tension (3% O2).  
Differently from normoxia (21%O2), MEFs cultured at 3% oxygen levels (hypoxia) did not 
undergo stress-induced senescence, crisis and spontaneous immortalization and grew 
indefinitely maintaining functional checkpoints231. However, MEFs cultured at 3% O2 
accumulated p16 and p19/Arf levels to a similar extent of senescent cells without 
undergoing a cell cycle arrest231 (Figure 1a and 1b). 
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The expression of PRC2 and PRC1 components such as Ezh2, Suz12, Eed and Ring1b 
remained stable during the passages of MEFs in 3%O2. Differently, PcGs levels were 
reduced in MEFs cultured at 21% oxygen levels in parallel to the appearance of markers of 
cellular senescence (Figure 1a and 1b). In contrast, strong differences in p53 activation 
were observed between normoxia and hypoxia, a result that is consistent with previous 
reports 231. The increased expression of p16 and p19/Arf further suggests that loss of PcG 
activity at 3%O2 is likely to have minor effects on Ink4a/Arf expression, potentially 
highlighting Ink4a/Arf-independent PcGs activities in normal cells.  
To test this possibility, we generated Ezh2 conditional knockout (cKO) MEFs (Ezh2 fx/fx) 
116 from mice that carried a 4-hydroxytamoxifen (OHT) inducible estrogen receptor fused 
to CRE recombinase (CRE-ERT2) that is constitutively expressed by the Rosa26 locus 
(R26) 232. After one week of OHT exposure, growth curves and BrdU incorporation assays 
showed that the proliferation of Ezh2 KO MEFs was strongly impaired (Figure 2a-c). 
 
Figure 1. MEF proliferation and PcG proteins accumulation. a,Cumulative population doublings of MEF 
grown at 3% or 21% O2. Insets show a representative picture of the MEF stained for senescence-associated β-
galactosidase activity (SA-β-gal) at passage 5. b, Immunoblots using the indicated antibodies with protein 
extracts obtained from MEF grown at 3% and 21% O2 at the indicated passages. β-tubulin served as loading 
control. 
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Similarly, the knockdown of Suz12 and Eed, (two essential PRC2 components41, 233) using 
stable expression of specific short-hairpin RNAs (shRNAs), blocked the proliferation of 
MEFs in 3%O2 and reduced their BrdU incorporation levels (Figure 3a-c and Figure 4a-c).  
 
 
 
 
 
 
 
Figure 2. Ezh2 knockout in low oxygen grown MEF. a, Growth curves of Ezh2 fx/fx and Ezh2 -/- CreERT2 
MEFs grown at 3% O2. Left panel shows crystal violet staining of cells at day 5 of growth curve. The graph 
represent the quantification of crystal violet absorbance at λ=590nm at the indicated time points. Error bars 
indicate SD, n=3. b, Immunoblots  using the indicated antibodies with protein extracts prepared from Ezh2 
fx/fx and Ezh2 -/- MEFs at day 5 of the growth curves. β-tubulin and total Histone H3 served as loading 
controls. c, Bar plot shows the percentage of BrdU incorporation measured by FACS analysis between Ezh2 
fx/fx and Ezh2 -/- MEFs. 
Figure 3. Suz12 knockdown in low oxygen grown MEF. Growth curves of MEFs infected with Empty or 
shSuz12 expressing lentivirus grown at 3% O2. Left panel shows crystal violet staining of cells at day 5 of 
growth curve. The graph represent the quantification of crystal violet absorbance at λ=590nm at the indicated 
time points. Error bars indicate SD, n=3. b, Immunoblots  using the indicated antibodies with protein extracts 
prepared from Empty or shSuz12 MEFs at day 5 of the growth curves. β-tubulin and total Histone H3 served 
as loading controls. c, Bar plot shows the percentage of BrdU incorporation measured by FACS analysis 
between Empty or shSuz12 MEFs. 
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Importantly, loss of PRC2 activity only led to a very modest increase of p16 and p19/ARF 
levels, to a slight increase in p53 levels and to p21 up-regulation (Figure 2-4). Although 
these results suggest independency from Ink4a/Arf expression, they cannot exclude a role 
of pRb and p53 in PRC2-dependent proliferation defects.  
2.2 The PRC2 complex regulates proliferation and development independently of 
Ink4a/Arf-p53-pRb axis 
To test if PcG-dependent proliferation defects rely on p16 and p19/Arf expression, we 
crossed the R26CreERT2-Ezh2 fx/fx mice with an Ink4a/Arf -/- strain219 and generated 
MEFs at low oxygen tension (Figure 5).  
 
 
 
 
 
 
 
Figure 4. Eed knockdown in low oxygen grown MEF. Growth curves of MEFs infected with shCtrl or 
shEed expressing lentivirus grown at 3% O2. Left panel shows crystal violet staining of cells at day 5 of 
growth curve. The graph represent the quantification of crystal violet absorbance at λ=590nm at the indicated 
time points. Error bars indicate SD, n=3. b, Immunoblots  using the indicated antibodies with protein extracts 
prepared from shCtrl or shEed MEFs at day 5 of the growth curves. β-tubulin and total Histone H3 served as 
loading controls. c, Bar plot shows the percentage of BrdU incorporation measured by FACS analysis 
between shCtrl or shEed MEFs. 
 
Figure 5. Immuoblot in MEF wt or Ink4a/Arf -/-. Immunoblots using p16 and p19/Arf specific antibodies 
with protein extracts prepared from Ezh2 fx/fx and Ezh2 -/- MEFs with an Ink4a/Arf wild type or Ink4a/Arf -/- 
background. β-tubulin served as loading control. 
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After 7 days of OHT exposure, loss of Ezh2 activity induced strong proliferation defects in 
absence of a functional p16 and p19/Arf response (Figure 6).  
 
 
 
 
 
 
 
Similarly, the proliferation of tip-tail fibroblasts (TTF) derived from the same strain, also 
displayed a compromised proliferation upon deletion of Ezh2 activity (Figure7).  
 
 
 
 
 
 
 
Consistent with this, the acute knockdown of Suz12 and Eed in Ink4a/Arf -/- MEFs further 
demonstrated that PRC2 controls proliferation independently of Ink4a/Arf expression 
(Figure 8 and Figure 9).  
 
 
Figure 6. Ezh2 knockout in Ink4/Arf -/- MEF. a, Growth curve measured with crystal violet (λ=590nm) of 
Ezh2 fx/fx and Ezh2 -/- Ink4a/Arf -/-, Cre-ERT2 MEFs. Error bars indicate SD, n=3 b, Western blot analysis 
of protein extracts from Ezh2 fx/fx and Ezh2 -/- Ink4a/Arf -/-, Cre-ERT2 MEFs  using the indicated antibodies. 
β-tubulin and total Histone H3 served as loading controls.  
Figure 7. Ezh2 knockout in Ink4/Arf -/- TTF. a, Growth curve measured with crystal violet (λ=590nm) of 
Ezh2 fx/fx and Ezh2 -/- Ink4a/Arf -/-, Cre-ERT2 MEFs. Error bars indicate SD, n=3 b, Western blot analysis 
of protein extracts from Ezh2 fx/fx and Ezh2 -/- Ink4a/Arf -/-, Cre-ERT2 MEFs  using the indicated antibodies. 
H3 served as loading controls. 
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To gain in vivo insights for these observations, we took advantage of the Suz12 KO mouse 
model that we previously generated233. Suz12 -/- embryos are blocked in embryonic 
development and die around 8.5 days post coitum (dpc) with strong proliferation defects233. 
We crossed Suz12 +/- mice into an Ink4a/Arf -/- background and tested whether loss of 
Ink4a/Arf expression could rescue its developmental and proliferative defects. Consistent 
with the results obtained with MEFs, the embryonic development of Suz12-Ink4a/Arf 
Figure 8. Suz12 knockdown in Ink4/Arf -/- MEF. a, Growth curve measured with crystal violet (λ=590nm) 
of Ink4a/Arf -/- MEFs infected with Empty or shSuz12 expressing lentivirus. Error bars indicate SD, n=3 b, 
Western blot analysis of protein extracts  from Ink4a/Arf -/- MEFs infected with Empty or shSuz12 
expressing lentivirus using the indicated antibodies. β-tubulin and total Histone H3 served as loading 
controls. 
 
Figure 9. Eed knockdown in Ink4/Arf -/- MEF. a, Growth curve measured with crystal violet (λ=590nm) 
of Ink4a/Arf -/- MEFs infected with shCtrl or shEed expressing lentivirus. Error bars indicate SD, n=3 b, 
Western blot analysis of protein extracts  from Ink4a/Arf -/- MEFs infected with Empty or shEed expressing 
lentivirus using the indicated antibodies. β-tubulin and total Histone H3 served as loading controls 
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double KO embryos remained impaired showing a complete size block at 8.5 dpc (Figure 
10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Suz12-/-; Ink4a/Arf-/- mouse embryogenesis. a, Pictures of embryos derived from Suz12 +/-, 
Ink4a/Arf -/- mating at the indicated developmental stages. b, PCR genotypes of the single embryos at each 
developmental stage are presented in a. c, Table summerizing all the statistics on the analysed embryos.  
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Although we cannot discern the contribution between proliferation and differentiation 
defects, this result highlights in vivo the Ink4a-Arf independent proprieties of PRC2 
activity and suggests that defective proliferation could play a role in the PRC2-dependent 
developmental defects.   
To further investigate the role of pRb and p53 pathways in PcG-dependent proliferation 
control, we took advantage of p53 (p53-/-) or pRb (pRb-/-) deficient MEFs (Figure 11 and 
Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
Knocking down Suz12 in both p53 -/- or pRb -/- MEF demonstrated that loss of PRC2 
activity induced proliferative defects also in the absence of either pRb or p53 functional 
responses (Figure 13 and Figure 14).  
Figure 12. PCR Genotypes of the pRb alleles . Agarose gel of samples coming from pRb fx/fx, pRb -/- and 
wt MEF. Water is used as negative control 
Figure 11. p53 Immunoblot in wt and p53 -/- MEF. p53 immunoblot in wild type and p53-/- MEF infected 
with Empty or shSuz12 expressing lentivirus. Vinculin served as loading control. 
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Moreover, to exclude that the two “arms” of the pathway could generate compensatory 
effects, we simultaneously inactivated p53 and pRb functions by expressing the Large T 
(LT) oncoprotein encoded by the simian virus 40 early region (SV40ER) in Ezh2 cKO 
MEFs217 (Figure 15). Also in this case, OHT-mediated deletion of the Ezh2 locus induced 
proliferation defects (Figure 16).  
Figure 13. Suz12 knockdown in p53-/- MEF. a, Growth curve measured with crystal violet (λ=590nm, top 
panels) in p53-/- MEFs infected with Suz12 specific shRNA expressing or empty lentiviral vectors. Error 
bars indicate SD, n=3 b, immunoblots of protein extracts using the indicated antibodies in p53-/- MEFs 
infected with Suz12 specific shRNA expressing or empty lentiviral vectors. β-tubulin and total Histone H3 
served as loading controls.   
Figure 14.  knockdown in pRb-/- MEF. a, Growth curve measured with crystal violet (λ=590nm, top 
panels) in pRb-/- MEFs infected with Suz12 specific shRNA expressing or empty lentiviral vectors. Error 
bars indicate SD, n=3 b, immunoblots of protein extracts using the indicated antibodies in p53-/- MEFs 
infected with Suz12 specific shRNA expressing or empty lentiviral vectors. β-tubulin and total Histone H3 
served as loading controls.   
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Figure 15. Immunoblot in Ezh2 fx/fx SV40 immortalized and wt MEF. Western blot with the indicated 
antibodies in SV40 immortalized or wt MEF Ezh2 fx/fx; Cre-ERT2. Vinculin served as loading control.  
Figure 16. Ezh2 knockout in SV40 immortalized MEF. a, Growth curve measured with crystal violet 
(λ=590nm) of Ezh2 fx/fx and Ezh2 -/- SV40, Cre-ERT2 MEFs. Error bars indicate SD, n=3 b, Western blot 
with the indicated antibodies in Ezh2 fx/fx and Ezh2 -/- SV40, Cre-ERT2 MEFs. β-tubulin and total Histone 
H3 served as loading controls. 
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Differently from cells with proficient cell cycle checkpoints, loss of Ezh2 activity did not 
induce a cell cycle arrest but a constant reduction in the proliferation rate of the MEFs and 
an overall impairment on colony formation ability (Figure 17 and Figure 18). Overall, 
these data demonstrate that PRC2 can control cellular proliferation independently from the 
Ink4a/Arf-pRb-p53 axis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. 3T3 like growth curve of Ezh2 fx/fx and Ezh2 -/- SV40 Cre-ERT2. a, 3T3-like assay 
performed with Ezh2 fx/fx and Ezh2 -/- SV40 Cre-ERT2 MEF. 106 cells per 10 cm dish were plated every 4 
days  and counted over a time of 16 days. b, Average population doublings for each day in Ezh2 fx/fx and 
Ezh2 -/- SV40 Cre-ERT2 MEF . Error bars indicate SD, n=3.  
Figure 18. Colony assay in Ezh2 fx/fx and Ezh2 -/- SV40 immortalized MEF. a, Colonigenic assays 
stained with crystal violet of Ezh2 fx/fx and Ezh2 -/- SV40 immortalized MEFs. b, Colonies quantification 
determined using ImageJ. Error bars indicate SD, n=3. 
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2.3 PRC2 controls cellular transformation in p53-pRb independent manner 
PRC2 components are frequently found highly expressed in human tumours56 and this can 
be mirrored in cell culture using cellular immortalization and transformation protocols 
(Figure 19).  
 
 
 
 
 
 
 
 
To assess whether PRC2 ability to control proliferation in a p53-pRb independent manner 
could be a determinant for cellular transformation, we expressed independently the H-
RASV12 and c-MYC oncogenes in R26CreERT2, Ezh2 cKO MEFs that were previously 
immortalized by SV40ER expression. First, we assayed the requirement of Ezh2 for the 
transformation of MEFs by expressing H-RASV12 in SV40ER immortalized Ezh2-/- 
MEFs (condition defined as PRE, Figure 20a). Then, we evaluated the requirement of Ezh2 
for the maintenance of the transformed phenotype by knocking it out in MEFs that were 
already transformed by H-RASV12 expression (condition defined as POST, Figure 20b). 
By performing colony and foci formation assays in cell culture, we demonstrated that loss 
of Ezh2 activity both prevented (PRE condition) and impaired (POST condition) cellular 
transformation in SV40 H-RASV12 transformed MEF (Figure 21).  
Figure 19. PRC2 components levels in wt or transformed MEF. Immunoblots with the indicated 
antibodies of wild type and SV40ER H-RASV12 expressing MEFs protein extracts. β-tubulin served as 
loading control. 
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Figure 20. H-RASV12 and Ezh2 expression in MEF SV40 H-RASV12 in PRE and POST conditions. a, 
(PRE condition) H-RASV12 expression in SV40 immortalized Ezh2 fx/fx or Ezh2 -/- MEF. β-tubulin served 
as loading control. b, (POST condition) Ezh2 and H3K27me3 levels  in SV40 H-RASV12 transformed Ezh2 
fx/fx or Ezh2 -/- MEF. β-tubulin and histone H3 served as loading control. 
 
Figure 21. Colony and Foci assay in Ezh2 knockout SV40 H-RASV12 transformed cells. a, Colonigenic 
assay stained with crystal violet of SV40ER H-RASV12 transformed Ezh2 fx/fx or Ezh2 -/- CreERT2 MEFs. b, 
Colonies in a were quantified using ImageJ. Error bars indicate SD, n=3. c, Foci formation assay stained with 
Giemsa of SV40ER immortalized Ezh2 fx/fx or Ezh2 -/- CreERT2 MEFs that stably expressed H-RASV12. 
PRE indicates that SV40ER immortalized Ezh2 fx/fx, CreERT2 MEFs were exposed to OHT treatment before 
H-RASV12 expression. The POST condition indicates that H-RASV12 was expressed in SV40ER 
immortalized, CreERT2 Ezh2 fx/fx MEFs before OHT treatment. d, Foci in c were and quantified using 
ImageJ. Error bars indicate SD, n=3. 
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We then explore the possibility that these findings could be recapitulated also in vivo. To 
address this issue we took both MEF Ezh2 fx/fx and Ezh2 -/- SV40 H-RASV12 
transformed MEF coming from the PRE or the POST condition and we inoculated them in 
immunocompromised mice. As shown by the tumour volume, the masses formed with 
Ezh2-/- MEF are dramatically reduced or sometimes absent compared to those generated 
by Ezh2 fx/fx MEF in both PRE and POST conditions (Figure 22).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consistent with these observations we were able to obtain similar results using another 
well-known oncogene such as C-MYC to transform SV40 immortalized Ezh2 cKO MEF 
(Figure 23). Together, these results demonstrate that Ezh2 is required for the 
  
  
Figure 22. Injection of Ezh2 fx/fx and Ezh2 -/- SV40 H-RASV12 transformed MEF in nude mice. a, 
Pictures of nude mice and isolated tumour masses at 14 days post-injection of Ezh2 fx/fx and Ezh2 -/- SV40 
H-RASV12 transformed MEF (PRE condition). b, Average increase of tumour size (volume) at the 
indicated time (left) and the weights of the tumour masses (right) shown in a. Error bars indicate SD, n=10. 
c, Same outline of a injecting cells of the POST condition. d, same as b referred to c. 
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transformation and maintenance of tumour growth even though the p53 and pRb pathways 
are inactivated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 Redundant role of PRC1 in cells proliferation and transformation control 
PRC1 shares several functions with PRC2 including the control of cell proliferation. 
Despite PRC2-independent recruitment of PRC1 sub-complexes was extensively 
described184, PRC1 and PRC2 retain a large part of common regulatory pathways234. 
Similar to PRC2, the expression of Ring1b (the central catalytic subunit for all forms of 
PRC1) is maintained during culture of MEFs under hypoxic conditions (Figure 1b).  
  
Figure 23. Colony and Foci assay in Ezh2 knockout SV40 c-myc transformed cells. a, Colonigenic 
assay stained with crystal violet of SV40ER immortalized Ezh2 fx/fx or Ezh2 -/- CreERT2 MEFs expressing 
c-myc. b, Colonies in a were quantified using ImageJ. Error bars indicate SD, n=3. c, Foci formation assay 
stained with Giemsa of SV40ER immortalized Ezh2 fx/fx or Ezh2 -/- CreERT2 MEFs that stably expressed 
c-myc. PRE indicates that SV40ER immortalized Ezh2 fx/fx, CreERT2 MEFs were exposed to OHT 
treatment before H-RASV12 expression. The POST condition indicates that c-myc was expressed in 
SV40ER immortalized, CreERT2 Ezh2 fx/fx MEFs before OHT treatment. d, Foci in c were and quantified 
using ImageJ. Error bars indicate SD, n=3. 
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To extend our observations regarding the Ink4a/Arf, pRb and p53 independent role of 
PRC2 in regulating cell proliferation and transformation, we generated R26CreERT2 mice 
that carry a constitutively deleted allele for Ring1a (Ring1a -/-, Figure 24) and a Cre-
dependent conditional allele for Ring1b (Ring1b fx/fx)235.  
 
 
 
 
 
MEFs generated at 3%O2 from these mice and exposed to OHT treatment for one week, 
displayed a rapid cell cycle arrest (Figure 25). Compared to PRC2, loss of PRC1 activity 
induced a significant activation of p16 and p19/Arf expression that correlated with p53 
stabilization and activation (Figure 25b). This result suggests that PRC1 repression of 
Ink4a/Arf may be largely independent on PRC2 activity and that the increased levels of 
p16 and p19/Arf could still induce a cell cycle arrest in Ring1a/b KO hypoxic cultures. 
 
 
 
  
 
 
 
 
Figure 24. Ring1a PCR genotype. Agarose gel representing wt and KO Ring1a alleles PCR products . 
Ring1a heterozigote (+/-), knockout (-/-) and wt MEF DNA amplified with specific primers. Water is used as 
negative control. 
Figure 25. Ring1b and Ring1a depletion in low oxygen grown MEF. a, Growth curves of Ring1b fx/fx 
and Ring1b -/- Ring1a -/- CreERT2 MEFs grown at 3% O2. Left panel show crystal violet staining of cells at 
day 5 of growth curve. The graph represent the quantification of crystal violet absorbance at λ=590nm at the 
indicated time points. Error bars indicate SD, n=3. b, Immunoblots  using the indicated antibodies with 
protein extracts prepared from Ring1b -/- Ring1a -/- CreERT2 MEFs at day 5 of the growth curves. β-tubulin 
and total Histone H2a served as loading controls. c, Bar plot shows the percentage of BrdU incorporation 
measured by FACS analysis between Ring1b -/- Ring1a -/- CreERT2 MEFs. 
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 Thus, we crossed these mice with an Ink4a/Arf -/- strain and tested if PRC1 activity was 
required for the proliferation of MEFs that cannot express p16 and p19/Arf (Figure 26).  
 
 
 
 
 
 
Consistent with our previous results, loss of PRC1 activity in Ink4a/Arf -/- MEFs impaired 
cellular proliferation under hypoxia conditions (Figure 27).  
 
 
 
 
 
 
 
 
 
To further exclude that pRb and p53 activation could still mediate a cell cycle arrest, we 
inhibited their activity by expressing SV40ER in Ring1a -/-, Ring1b fx/fx R26CreERT2 
MEFs (Figure 28).  
 
Figure 26. Immuoblot in Ring1a -/- Ring1b fx/fx MEF or Ring1a -/- Ring1b fx/fx Ink4a/Arf -/- MEF. 
Immunoblots using p16 and p19/Arf specific antibodies with protein extracts prepared from Ring1b fx/fx 
Ring1a -/- and Ring1b -/- Ring1a -/- MEFs with an Ink4a/Arf wild type or Ink4a/Arf -/- background. β-
tubulin served as loading control. 
 
Figure 27. Ring1a-/- and Ring1b knockout in Ink4/Arf -/- MEF. a, Growth curve measured with crystal 
violet (λ=590nm) of Ring1b fx/fx and Ring1b -/- Ring1a -/- Ink4a/Arf -/-, Cre-ERT2 MEFs. Error bars 
indicate SD, n=3 b, Western blot analysis of protein extracts from of Ring1b fx/fx and Ring1b -/- Ring1a -/- 
Ink4a/Arf -/-, Cre-ERT2 MEFs  using the indicated antibodies. β-tubulin and total Histone H2a served as 
loading controls. 
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As for Ezh2 KO MEFs, the genetic inactivation of the PRC1 activity strongly inhibited 
cellular proliferation and colonigenic potential in the absence of a functional pRb and p53 
pathway (Figure 29 and Figure 30).  
 
 
 
 
 
 
 
 
 
Figure 28. Immunoblot in Ring1b fx/fx Ring1a -/- SV40 and SV40 H-RASV12 MEF. Western blot with 
the indicated antibodies in SV40 immortalized or SV40 H-RASV12 transformed MEF Ring1a -/-, Ring1b fx/fx 
Cre-ERT2. Vinculin served as loading control 
Figure 29. PRC1 knockout in SV40 immortalized MEF. a, Growth curve measured with crystal violet 
(λ=590nm) of Ring1b fx/fx and Ring1b -/- Ring1a -/-, SV40, Cre-ERT2 MEFs. Error bars indicate SD, n=3 
b, Western blot with the indicated antibodies in Ring1b fx/fx and Ring1b -/- Ring1a -/-, SV40, Cre-ERT2 
MEFs. β-tubulin and total Histone H2a served as loading controls. 
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To further test whether PRC1 activity is required for the transformation of MEFs and 
tumour growth, we inactivated Ring1b before or after H-RASV12 ectopic expression in 
Ring1a -/- SV40 immortalized MEF (respectively PRE and POST, Figure 30).  
  
 
 
 
 
 
 
 
Like it happens for the PRC2 depletion, loss of Ring1a and Ring1b functions strongly 
affects colonies and foci formation as well as in vivo tumour growth in nude mice, thus 
demonstrating that PRC1 is essential for the acquisition (PRE) and the maintenance 
(POST) of oncogenic potential in a pRb-p53 independent manner (Figure 32-33).  
Figure 31. Ring1a-/- and Ring1b knockout in SV40 H-RASV12 transformed MEF. a, Western blot 
with the indicated antibodies in Ring1b fx/fx and Ring1b -/- Ring1a -/-, SV40, H-RASV12 Cre-ERT2 
transformed MEFs. β-tubulin and total Histone H2a served as loading controls. 
 
Figure 30. Colony assay in PRC1 knockout in SV40 immortalized MEF SV40 immortalized MEF. a, 
Colonigenic assays stained with crystal violet of Ring1b fx/fx and Ring1b -/- Ring1a -/-, SV40, Cre-ERT2 
MEFs.b, Colonies quantification determined using ImageJ. Error bars indicate SD, n=3. 
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Figure 32. Colony and Foci assay in Ring1b and Ring1a knockout SV40 H-RASV12 transformed 
cells. a, Colonigenic assay stained with crystal violet of Ring1b fx/fx and Ring1b -/- Ring1a -/-, SV40, H-
RASV12 Cre-ERT2 transformed MEFs. b, Colonies in a were quantified using ImageJ. Error bars indicate 
SD, n=3. c, Foci formation assay stained with Giemsa of Ring1b fx/fx and Ring1b -/- Ring1a -/-, SV40, H-
RASV12 Cre-ERT2 MEFs. PRE indicates that SV40ER immortalized Ring1b fx/fx and Ring1b -/- Ring1a -/- 
CreERT2 MEFs were exposed to OHT treatment before H-RASV12 expression. The POST condition 
indicates that H-RASV12  was expressed in SV40ER immortalized, Ring1b fx/fx Ring1a -/- CreERT2 
before OHT treatment. d, Foci in c were and quantified using ImageJ. Error bars indicate SD, n=3. 
Figure 33. Injection of Ring1b and Ring1a knockout SV40 H-RASV12 transformed MEF in nude 
mice. a, Pictures of nude mice and isolated tumour masses at 14 days post-injection of Ring1b fx/fx and 
Ring1b -/- Ring1a -/-, SV40, H-RASV12 Cre-ERT2 transformed MEFs. b, Tumor masses isolated from 
mice show in a. c, Average increase of tumour size (volume) at the indicated time (left) and the weights of 
the tumour masses (right) shown in b. Error bars indicate SD, n=10  
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These results were further supported by the rapid exhaustion of the self-renewing potential 
of normal and MYC-transformed hematopoietic stem cells upon inactivation of PRC1 
activity (Figure 34). Together, these results suggest the existence of alternative 
mechanisms of PcG-dependent proliferation control that could be in common among 
different cell types.  
 
 
 
 
 
 
 
 
 
 
2.5 PcG proteins control S-phase entry and DNA replication 
Since PcGs repressive activity is not exclusively recruited at the ink4a-Arf locus but 
potentially regulates the expression of more than 2500 genes in MEFs (Figure 35b), we 
hypothesised that additional transcriptional pathways could be under the direct 
transcriptional control of PcG proteins. To our surprise, despite the strong proliferation 
impairment (Figure 6), expression analyses performed in Ink4a/Arf -/- Ezh2 -/- MEF 
identified only 46 genes that were significantly up regulated upon loss of Ezh2 activity 
(Figure 35a). Differently, expression analyses performed in Ink4a/Arf +/+ Ezh2 -/- MEF 
identified 792 genes that were up regulated compared to Ezh2 fx/fx MEF of which only 31 
Figure 34.  PRC1 activity depletion in hematopoietic stem cells. Hematopoietic stem cells self-renewal 
assay (methylcellulose assay) performed with lineage negative (lin-) bone marrow purified cells from 
Ring1a -/-, Ring1b fx/fx Cre-ERT2 mice in absence (a) or presence (b) of c-MYC ectopic lentiviral-driven 
expression and treated with EtOH or OHT. Bar plots indicates the number of colonies formed on 
methylcellulose matrix 7 days after each plating. An equal amount of Ring1a -/-, Ring1b fx/fx Cre-ERT2 
cells isolated from the first passage were also re-plated in the presence of OHT to allow conditional alleles 
deletion (passage 2, +OHT treatment).  
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were found commonly regulated between Ink4-Arf proficient and KO MEFs (Figure 35a). 
Moreover, a few proportion of H3K27me3 enriched genes1 was transcriptionally up-
regulated upon inactivation of Ezh2 activity in both WT and Ink4a-Arf-/- MEFs 
(respectively ~7% and ~0.4%) of WT and Ink4a-Arf-/- MEFs (Figure 35b), suggesting 
indirect transcriptional regulations that are prevalently dependent on the activation of cell-
cycle restriction checkpoints in Ink4a-Arf proficient MEFs (Figure 35b). Together, these 
data point towards a transcriptional-independent mechanism by which PcGs can control 
cellular proliferation.  
 
 
 
 
 
 
 
 
Loss of Suz12 expression from serum starved quiescent human fibroblasts impairs the cell 
cycle re-entry measured by incorporation of BrdU233. This result suggests that loss of 
PRC2 activity could affect the progression of G1 or S-phase. The finding that PcG proteins 
can remain associated with chromatin during DNA synthesis236, together with the 
localization of PRC2 subunits at sites of ongoing DNA replication237, potentially suggests 
a direct link between PcG activities and DNA replication. To test this, we synchronized 
Ezh2 fx/fx and Ezh2-/- MEFs at the G1/S boundary with a double-thymidine block, allowed 
S-phase re-entry for 30 minutes in the presence of BrdU, and measured DNA synthesis by 
flow cytometric analyses (FACS) with a BdrU specific antibody. Due to the polyploidy of 
Figure 35. Transcriptional changes in Ezh2 -/- MEF. a. Venn diagrams representing the overlap of genes 
up-regulated in either Ezh2 fx/fx or Ink4a/Arf -/- Ezh2 fx/fx MEF treated with OHT (Ezh2 -/-) respect to 
EtOH (Ezh2 fx/fx) with a minimal fold difference of 1.5. b,The diagrams represent the same overlap of a 
respect to previously characterized1 H3K27me3 enriched promoters in WT MEFs. 
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RASV12 or MYC-transformed MEFs238, 239 (Figure 35 and Figure 36), we restricted BrdU 
measurements to the 2C population to avoid cross-contaminations of G1/S boundaries. 
This analysis highlighted a reduced number of cells that synthesized DNA in Ezh2 -/- 
MEFs, suggesting direct defects of DNA replication in the absence of PRC2 activity 
(Figure 36 and Figure 37).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36.  FACS plot of SV40 H-RASV12 Ezh2fx/fx and Ezh2 -/- MEF re-entry in S-phase. a, FACS 
dot plot of SV40 H-RASV12 Cre-ERT2 transformed Ezh2 fx/fx MEFs 7 days after EtOH (Ezh2 fx/fx) and 
OHT (Ezh2 -/-) treatment fixed 30 minutes after release from a double-thymidine G1/S block in the 
presence of BrdU. The numbers near the boxes indicated the relative cell percentage present in each box. 
b,The bar plots represent the relative percentage of cells with 2C DNA content present in the highlighted 
boxes in a(BrdU negative, intermediate and BrdU positive). 
Figure 37.  FACS plot of SV40 c-MYC Ezh2fx/fx and Ezh2 -/- MEF re-entry in S-phase. FACS dot 
plot of SV40 c-MYC Cre-ERT2 transformed Ezh2 fx/fx MEFs 7 days after EtOH (Ezh2 fx/fx) and OHT 
(Ezh2 -/-) treatment fixed 30 minutes after release from a double-thymidine G1/S block in the presence of 
BrdU. The numbers near the boxes indicated the relative cell percentage present in each box. b,The bar 
plots represent the relative percentage of cells with 2C DNA content present in the highlighted boxes in 
a(BrdU negative, intermediate and BrdU positive). 
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Consistent with this, Ezh2 proficient cells displayed a high degree of overlap between core 
PRC2 (Suz12) and PRC1 (Ring1b) subunits with sites of BrdU incorporation during S-
phase (Figure 38). Loss of Ezh2 strongly reduced Suz12 levels and severely affects its 
association to BrdU signal. Furthermore Ezh2 strongly impairs Ring1b association with 
newly synthesized DNA (Figure 38) and suggested a hierarchical recruitment at replication 
sites between PRC2 and PRC1 as described for several target genes184.  
 
 
 
 
 
 
 
 
 
 
 
 
To test whether PcG deficiency could affect DNA replication, we performed DNA 
molecular combing experiments, which allow the quantitative study of individual DNA 
replication events240. Ezh2 fx/fx and Ezh2 KO MEFs initially pulse-labelled with IdU for 20 
minutes and then immediately pulse-labelled with CldU for other 20 minutes. These two 
pulses allow to label active replicating forks with 2 different thymidine analogues. Pulse labelling cells with two analogues allows the analysis of more replication parameters 
Figure 38. PcGs and BrdU localization in S-phase in Ezh2 fx/fx and Ezh2 -/- Ink4a/Arf -/- MEFs. a and 
b, Confocal immunofluorescence images of Ink4a/Arf -/-; Ezh2 fx/fx and Ink4a/Arf -/- Ezh2 -/- MEFs 2 hours 
after release from double-thymidine G1/S block in the presence of BrdU stained with the indicated 
antibodies. c and d, Bar plots indicates the average Mender’s co-localization coefficient among all images Z-
stacks for each cell stained as in a. Error bars indicate SD. n is indicated in the figure.   
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than in the case of labelling with a single analogue. Indeed, double labelling allows the precise evaluation of for the symmetry of fork progression, inter-origin distances, which can only be inferred in case of single labelling. Labelled cells were included into 
agarose plugs then the DNA was extracted and slowly (300µm/s or 2 Kb/s) combed on 
hydrophobic glass slides. Then IdU and CIdU incorporated on DNA fibres combed on 
glass slides were detected by fluorescent staining, together with anti-single-strand DNA 
antibody (to identify fibres). First, we measured the overall velocity of replication forks by 
dividing the length of the signal coming from analogues staining (in kb) by the analogue 
pulsing time (in minutes), also considering that each µm of signal correspond to 2 kb240. 
When this was measured in our Ezh2 cKO MEF, while Ezh2 proficient MEFs displayed a 
unimodal fork speed distribution (centred around a mean fork velocity of 2.02 Kb/min), 
Ezh2 -/- cells displayed an overall slower velocity (mean velocity 1.79 kb/min) and a 
bimodal distribution highlighting the presence of a DNA replication fork population 
significantly slower (Figure 39).  
 
 
 
 
 
 
 
 
Next, we determined the replication symmetry by measuring the length of newly 
synthesized DNA and comparing the fork progression of the left and right arms of the 
DNA replication bubble departing in opposite directions from the same DNA replication 
Figure 39.  Distribution of fork speed values in Ezh2 fx/fx and Ezh2 -/- SV40 H-RASV12 transformed 
MEFs. Distribution of the replication speed for all forks between  SV40 immortalized Ezh2 fx/fx MEFs that 
stably expressed H-RASV12, 7 days after EtOH (Ezh2 fx/fx) and OHT (Ezh2 -/-) treatment. N, mean and 
standard error are indicated in the figure. p-value was determined by Chi-squared test. 
  49  
origin. To analyse the replication forks symmetry we firstly identify replication origins that 
consist in fibre zones with no signal flanked by IdU staining (first pulse marked in red). 
After origin localization we consider arbitrary left and right forks of which we measured 
respectively the length of the signal coming from the two different nucleotide analogues. 
We observed three main patterns of DNA replication: “symmetric fork progression” in 
which DNA replication fork progression is comparable between left and right forks (IdU 
and CldU left/right ratio less than 30% difference, Figure 40 top panel), “asymmetric fork 
progression”, in which the difference between the two DNA replication forks is more than 
30%, (IdU and CldU left/right ratio > 30% difference, Figure 40 middle panel) and 
”unidirectional fork progression” in which only one DNA replication fork depart from one 
origin (Idu signal absent in one of the two direction, Figure 40 bottom panel). Following 
this classification, the analysis of Ezh2 fx/fx and Ezh2 KO replicating DNA demonstrated 
that Ezh2 -/- MEFs accumulated a greater number of asymmetric and unidirectional DNA 
replication forks (Figure 41).  
 
 
 
 
 
 
 
 
 
 
Figure 40. Replication forks symmetry classification. Representative spinning disk confocal microscopy 
images of DNA combing performed in the cells presented in Figure 38 and stained with specific antibodies 
against nucleotide analogues indicated in the figure. DNA fibres were visualized using ssDNA specific 
antibody (marked as DNA in the figure).      
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To test whether the fork speed reduction was associated with asymmetric fork progression 
within individual replicons, we selected only the fork speed values deriving from replicons, 
regardless their levels of symmetry (all fork speed in replicons, Figure 42).  
 
 
 
 
 
 
 
 
 
 
Figure 42. Distribution of fork speed values in replicons. Distribution of the replication forks speed in 
replicons  between SV40 immortalized Ezh2 fx/fx MEFs that stably expressed H-RASV12, 7 days after 
EtOH (Ezh2 fx/fx) and OHT (Ezh2 -/-) treatment. N, mean and standard error are indicated in the figure. p-
value was determined by Chi-squared test.  
Figure 41. Symmetry based distribution of replication forks in Ezh2 fx/fx and Ezh2 -/- SV40 H-
RASV12 transformed MEFs. a, dot plot colour coded representing symmetric (light blue) asymmetric 
bidirectional (green) and asymmetric unidirectional (red) replication forks in SV40 immortalized Ezh2 fx/fx 
MEFs that stably expressed H-RASV12, 7 days after EtOH (Ezh2 fx/fx) and OHT (Ezh2 -/-) treatment. 
Dotted lines indicate the 30% ratio tolerance  applied to define symmetric fork progression N is mentioned 
in the figure. b, bar plot quantification of a 
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Next, we analysed fork speed only in symmetric DNA replication operons, thus excluding 
asymmetric ones, and found a consistent reduction in fork speed in Ezh2 -/- MEFs 
compared to wild-type MEFs (symmetric fork speed in replicons, Figure 43). 
 
 
 
 
 
 
 
 
 
Overall these results show that lack of Ezh2 increases the rate of DNA replication fork 
stalling, as demonstrated by increased levels of asymmetric and unidirectional forks. In 
addition, Ezh2 inactivation also reduces DNA replication fork speed, but, surprisingly, this 
is not a peculiarity only of stalled (asymmetric) DNA replication forks. 
In yeasts, increased DNA replication fork stalling can trigger firing of dormant origins241. 
To test this possibility, we analysed the impact that loss of Ezh2 expression have on DNA 
replication origin firing. Accordingly to an increased impairment in DNA replication, Ezh2 
KO cells showed an increased number of active replication origins as inferred by the 
decreased inter-origin distances (IODs) of Ezh2 -/- respect to Ezh2 fx/fx cells (Figure 44). 
These differences are maintained also when the IOD was analysed on DNA fibres longer 
than three times the average of fibres length242 (Figure 44b).  
 
Figure 43.  Distribution of symmetric fork speed values in replicons. Distribution of the symmetric 
replication forks speed in replicons  between SV40 immortalized Ezh2 fx/fx MEFs that stably expressed H-
RASV12, 7 days after EtOH (Ezh2 fx/fx) and OHT (Ezh2 -/-) treatment. N, mean and standard error are 
indicated in the figure. p-value was determined by Chi-squared test. 
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Furthermore these results are not a consequence of increased DNA fibres fragmentation of 
Ezh2 KO samples as both Ezh2 fx/fx and Ezh2 -/- DNA preparations displayed overlapping 
DNA lengths distribution (Figure 45).  
 
 
 
 
 
 
 
 
 
 
Figure 44.  Inter Origin Distances (IODs) in Ezh2 fx/fx and Ezh2 -/- SV40 H-RASV12 transformed 
MEFs. a, Distribution of inter-origin distances (IOD) measured for all DNA fibres between Ezh2 fx/fx and 
Ezh2-/- cells described in Figure 38. Bar plots show the average IODs of Ezh2 fx/fx and Ezh2-/- cells. Error 
bars indicate SD. n is indicated in the figure. p-value was determined by Chi-squared test. b, same as in a 
calculating only IODs coming from DNA fibres 3 times longer than the average of fibres length. 
 
Figure 45. Distribution of fiber lengths in DNA combing analyses a, Distribution of the fibres length 
used in DNA combing analyses (Figure 38-42). b, Bar plots of mean and median values of fibres length 
referred to a 
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Finally, since altered DNA replication parameters, and in particular DNA replication 
stalling events, may trigger DNA damage response (DDR) activation, we monitored DDR 
signalling at the single-cell level, by the study of 53BP1 foci formation in S-phase243.  
Ezh2 deficient MEFs present an increased number of 53BP1 foci respect to WT cells 
(Figure 46). Overall, these data demonstrate that PcG activity localizes at sites of DNA 
synthesis and plays an important role in regulating the normal progression of DNA 
replication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. 53bp1 staining in Ezh2 fx/fx and Ezh2 -/- SV40 H-RASV12 transformed MEFs. a, Confocal 
immunofluorescence images of SV40ER immortalized Ezh2 fx/fx MEFs that stably expressed H-RASV12 7 
days after EtOH (Ezh2 fx/fx) and OHT (Ezh2 -/-) treatment, 30 minutes after release from a double-
thymidine G1/S block stained with 53BP1 specific antibody. b, Box plot represents the number of 53bp1 
foci in each cell. Foci number was quantified using ImageJ. n is indicated in the figure. p-value was 
determined with paired t-test. 
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Discussion 
 
In the present thesis, we provided genetic proofs for the role of PRC2 and PRC1 in 
controlling normal and neoplastic cells proliferation independently of Ink4a/Arf-p53-pRb 
cell cycle regulation. This finding has a particular relevance in the context of tumour 
development where loss of Ink4a/Arf, pRb and/or p53 response is a hallmark for all type of 
human tumours215.  
Ezh2 enzymatic activity has become an appealing pharmacological target to hamper 
tumour spreading127-129 and our data genetically supports the effectiveness of PcG 
inhibition for cancer treatment. For example, it has been recently demonstrated that diffuse 
large B cell lymphomas (DLBCL) that carry hyper-activating mutations of EZH2 
(DLBCLs frequently present defective p53 response244, 245), can be efficiently treated with 
EZH2 selective compounds127.  
Here we demonstrated the tumorigenic cells dependency on both PRC1 and PRC2 activity. 
Precisely we were able to show that the two complexes are definitely required for the 
initial acquisition of the transformed phenotype. This notion is of particular importance, 
because this is one of the few evidences, so far reported, that PRC1 or PRC2 abrogation in 
immortalized cells prevents the acquisition of transformed phenotype upon expression of a 
strong oncogene such as H-RASV12 or C-MYC. Furthermore the importance of this issue 
consists in supporting a potential strategy to target PcGs also in low aggressive tumours in 
which severe tumorigenic features, such as metastatic potential, have not been acquired 
yet. 
Our findings suggest a scenario where PcG proteins exert a parallel control over DNA 
replication and Ink4a/Arf transcription. Loss of PcG activities in normal cells, will affect at 
the same time cellular proliferation, by favouring the efficient replication of the DNA, and 
cell cycle checkpoints, by regulating the transcription of Ink4a/Arf (Figure 45). While loss 
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of Ink4a/Arf repression can activate cell cycle checkpoints, a defective DNA replication 
will trigger a parallel stress response to potentiate Ink4a/Arf, pRb and p53 dependent cell 
cycle arrest in a positive feedback loop (Figure 47). In absence of functional checkpoints, 
cells will not undergo a cell cycle arrest but their proliferation will still result dependent on 
PcG activity (Figure 47). An additional layer of complexity could come from PcG-
dependent transcriptional regulation of additional targets. This could involve the de-
repression of lineage specific genes, which would result essential for the maintenance of 
cellular identity; or the activation of a common set of targets genes with anti-proliferative 
function in all cell types. Although we cannot exclude these contributions, genome-wide 
transcription analysis, performed in Ink4a/Arf -/- MEFs, before and after Ezh2 deletion, did 
not show any relevant transcriptional effects in the presence of compromised cellular 
proliferation (Figure 6 and Figure 35) as also showed by a recent study in SUZ12 
knockdown cells183.  
Tumour cells are exposed to continuous replication stresses imposed by the activity of 
oncogenic signals. Common examples are the constitutive activation of RAS signalling or 
the overexpression of the MYC proto-oncogene 246, 247. When replication stress is coupled 
to defective cell cycle checkpoints, it results in the escape from cellular senescence. At the 
same time, this prolonged replicative stress promotes the instability of cancer cell genomes 
248. This could suggest that the direct role in regulating DNA replication processes could 
render cancer cells more sensitive to PcG inhibition. The finding that PcG proteins co-
localize and favour the progression of DNA replication suggests a direct implication of 
PcG activity with the replication of the DNA. PcGs could either play a role in origin firing, 
as depict by the decreased inter-origin distance of Ezh2 -/- MEFs, or they could be 
involved in chromatin dynamics during the progression of the replication forks. 
Alternatively, PcGs could play a role in regulating the collision between RNA transcription 
and DNA replication, for example through their ability to bind and disassemble the RNA 
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polymerase II complex249. This last hypothesis is currently under investigation due to new 
very recent and preliminary results we obtained from the purification of both PRC1 and 
PRC2 during S-phase (see Appendix).  
Together, our data provide evidences for a novel role of PcG proteins in regulating cellular 
proliferation that further explains the requirement of PcG activity for the growth of normal 
and cancer cells paving the way for the understanding of novel mechanisms of 
proliferation control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47.  Inter Origin Distances (IODs) in Ezh2 fx/fx and Ezh2 -/- SV40 H-RASV12 transformed 
MEFs. a, Distribution of inter-origin distances (IOD) measured for all DNA fibres between Ezh2 fx/fx and 
Ezh2-/- cells described in Figure 38. Bar plots show the average IODs of Ezh2 fx/fx and Ezh2-/- cells. Error 
bars indicate SD. n is indicated in the figure. p-value was determined by Chi-squared test. b, same as in a 
calculating only IODs coming from DNA fibres 3 times longer than the average of fibres length. 
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CHAPTER 4: Appendix 
 
To understand whether PRC1 and PRC2 associate with new partners in S phase we 
recently generated two MEF BirA lines: one stably expressing a Flag-Avi-Ring1b protein 
and the other expressing a Flag-Avi-Eed protein. These two MEF cell lines were 
synchronized at the G1/S boundary by a double thymidine block and then they were 
allowed to enter S phase for 1 hour. At that time we performed a double step purification 
for tagged Ring1b and Eed proteins coupled to mass spectrometry analyses to identify new 
PRC1 and PRC2 interactors in S-phase. The preliminary results indicate that several 
DNA/RNA helicases and RNA binding proteins also involved in RNA splicing interact 
with both PRC1 and PRC2 (Figure 48 and Figure 49). In the light of our results on PRC1 
and PRC2 involvement in DNA replication we speculate that their interaction with 
DNA/RNA helicases could play a direct role in the process. We hypothesize that these 
helicases may solve R-loops facilitating DNA replication when this collides with the 
transcriptional machinery250. We also speculate that, in concert, the role for PcG proteins in 
this context could consist in a transient local transcriptional repression that allows the 
replication of the DNA. We are currently investigating these hypotheses to better 
understand the molecular mechanism the underlies PcG control on DNA replication. 
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Gene names Peptides Ring1b 
Peptides 
Empty 
Sequence 
coverage 
Ring1b [%] 
Sequence 
coverage 
Empty [%] 
iBAQ 
Ring1b 
iBAQ 
Empty 
Ring1b 20 3 58,6 9,8 2,23E+07 2,57E+04 
Ywhaz 8 0 33,5 0 5,56E+05 0,00E+00 
Srsf1 11 0 37,2 0 4,09E+05 0,00E+00 
Srsf7 6 0 22,1 0 1,98E+05 0,00E+00 
Pabpc1;Pabpc6 19 0 28,6 0 1,44E+05 0,00E+00 
Ywhaq 6 0 24,5 0 1,37E+05 0,00E+00 
Srsf6 7 1 19,5 2,7 1,16E+05 1,05E+03 
Ywhag 6 0 24,7 0 9,34E+04 0,00E+00 
Tra2b 4 0 17,7 0 8,03E+04 0,00E+00 
Ddx5 7 1 11,7 1,3 5,58E+04 3,95E+03 
Ywhae 4 0 16,1 0 5,28E+04 0,00E+00 
Sfn 4 0 14,9 0 5,08E+04 0,00E+00 
Ell 7 1 12,1 1,7 3,40E+04 2,72E+03 
Hnrnpc 4 1 12,5 4,2 3,30E+04 3,10E+03 
Magoh;              
Magoh-rs1;Magohb 3 0 18,5 0 3,22E+04 0,00E+00 
Srrm2 21 0 9,4 0 2,96E+04 0,00E+00 
Pabpc4;Gm10110 8 1 12,9 1,7 2,57E+04 4,15E+03 
Prmt5 4 0 6,6 0 2,15E+04 0,00E+00 
Ruvbl2 5 0 11,9 0 1,94E+04 0,00E+00 
Hnrnpk;Gm7964 4 0 10,6 0 1,82E+04 0,00E+00 
Hnrnph1;Hnrnph2 4 0 13,3 0 1,56E+04 0,00E+00 
Ywhah 3 0 11 0 9,16E+03 0,00E+00 
Ddx3x;D1Pas1;Ddx3y 7 0 11,5 0 7,96E+03 0,00E+00 
Ddx17 8 1 13,7 1,2 7,78E+03 0,00E+00 
Ruvbl1 3 0 8,1 0 6,85E+03 0,00E+00 
Ddx1 3 0 3,9 0 6,19E+03 0,00E+00 
 
 
 
 
 
 
 
 
Figure 48.  PRC1 partners in S-phase. MEF BirA Flag-Avi-Ring1b have been synchronized 
by double thymidine block and released in S-Phase for 1 hour. Nuclear extracts have undergone 
double step purification and the eluate analysed by mass spectrometry. In the table are listed a 
selection of proteins identified. Peptides Ring1b are the unique peptides of proteins listed 
retrieved in Flag-Avi-Ring1b IP. Peptides Empty are the unique peptides of the proteins listed 
retrieved in mock IP. Proteins sequence coverage and iBAQ index are also presented for each 
protein identified 
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Gene names Peptides Eed 
Peptides 
Empty 
Sequence 
coverage 
Eed [%] 
Sequence 
coverage 
Empty [%] 
iBAQ      
Eed 
iBAQ 
Empty 
Eed 31 6 63,3 15,2 3,89E+07 29985 
Setx 23 0 9,3 0 2,30E+04 0 
Ddx21 12 3 14,8 3,2 7,45E+04 1783,3 
Dhx15 12 4 15,3 4,7 4,14E+04 1975,4 
Prpf3 8 1 12,4 1,8 3,30E+04 0 
Cpsf1 7 1 5,3 0,8 1,21E+04 0 
Sf3b2 6 1 8,8 1,4 3,74E+04 1482,5 
Srsf10 6 4 26 15,3 2,20E+05 51269 
Upf1 6 0 6,3 0 1,79E+04 0 
Larp7 5 0 10,2 0 4,85E+04 0 
Prpf4 5 1 10,2 1,5 2,48E+04 0 
Cpsf2 4 0 5 0 1,46E+04 0 
Taf4a 4 0 4,2 0 1,05E+04 0 
U2surp 4 1 3,4 0,7 2,58E+03 1822,5 
Rbm15 4 0 3,7 0 1,65E+03 0 
Ncbp1 3 1 4,2 1,5 1,60E+04 1116,9 
Rbm10 3 0 3,9 0 2,47E+03 0 
Mov10 3 0 2,8 0 1,91E+03 0 
Fmr1 3 1 5,9 1,3 8,49E+02 0 
Prpf40a 2 0 2,3 0 1,74E+05 0 
Sfpq 2 0 3,1 0 4,35E+03 0 
Ddx20 2 0 2,3 0 2,42E+03 0 
Cpsf3 2 0 2,9 0 1,78E+03 0 
Pura 2 0 5,9 0 0,00E+00 0 
Pnn 2 0 2,5 0 1,88E+03 0 
Sltm 2 0 1,8 0 1,16E+03 0 
Rbm5 1 0 1,5 0 3,23E+03 0 
Rbm39 1 0 2,1 0 2,61E+03 0 
Ddx23 1 0 1,3 0 1,79E+03 0 
Taf6 1 0 1,8 0 1,74E+03 0 
Rbfox2;Rbfox1;Rbfox3 1 0 2,2 0 0,00E+00 0 
Polr1e 1 0 2,5 0 0,00E+00 0 
Taf11 1 0 5,7 0 0,00E+00 0 
Sf3b14 1 0 11,2 0 1,38E+04 0 
Tcof1 1 0 0,7 0 7,22E+02 0 
 
 
 
 
Figure 49.  PRC2 partners in S-phase. MEF BirA Flag-Avi-Eed have been synchronized by 
double thymidine block and released in S-Phase for 1 hour. Nuclear extracts have undergone 
double step purification and the eluate analysed by mass spectrometry. In the table are listed a 
selection of proteins identified. Peptides Eed are the unique peptides of proteins listed retrieved 
in Flag-Avi-Ring1b IP. Peptides Empty are the unique peptides of the proteins listed retrieved 
in mock IP. Proteins sequence coverage and iBAQ index are also presented for each protein 
identified 
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CHAPTER 5: Material & Methods 
 
5.1 Ethic statements 
 All mouse work has been conducted in accordance with the Italian and international 
legislations. 
5.2 MEF generation and grow conditions 
Mouse Embryonic Fibroblasts (MEFs) are primary cells derived from mice embryos. These cells are 
commonly used as proliferating differentiated cells to study a broad range of biological process such as 
cellular proliferation, cellular senescence, DNA damage response, etc... Conditional alleles are commonly 
used for inducible knock-out, allowing alleles deletion after cells derivation from the animal (in this case 
from the embryos). CRE recombinase is the enzyme required to delete the conditional allele, this enzyme 
could be fused with a mutated ligand binding site of the Estrogen Receptor (ER T2), this leads the Cre 
recombinase inactive (because is retained in the cytoplasm) until the ligand (4-hydroxytamoxifen) is 
provided. The expression of the Cre recombinase could be targeted in different cell types by expressing it 
under a cell type specific promoter or it could be stably expressed in virtually all cell types by expressing it 
under a house-keeping promoter. 
Thymidine G1/S synchronization is achieved by the feedback inhibition of CMP (5’-cytosine mono-
phosphate) to dCTP (5’-deoxycytosine triphosphate) conversion leading to low/absent dCTP for DNA 
synthesis in S-phase. Double Thymidine G1/S synchronization is performed to allow cells that were already 
in S-phase during the first synchronization (therefore blocked in that phase) to finish the S-phase and to be 
synchronized in the second thymidine synchronization. This procedure allows having virtually all the cells at 
the very initial stage of the S-phase.  
All MEFs have been derived from 13.5 dpc embryos. Rosa26 CRE-ERT2, Ezh2 knockout, 
Ink4a/Arf knockout, Suz12 knockout, p53 knockout, pRb knockout Ring1a knockout, 
Ring1b knockout and Rosa26 BirA genes used in this work have been described elsewhere 
116, 218, 219, 235, 251, 252. In all the experiments, low passages MEFs have been grown in 
DMEM medium supplemented with 10% fetal bovine serum (Euroclone), non-essential 
amino acids (Gibco), sodium pyruvate (Gibco) and 1% penicillin/streptomycin (Gibco), in 
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a CO2 incubator (5% CO2) with reduced oxygen tension (3% oxygen) if not differently 
specified. MEFs were passaged every 3-4 days. To induce CRE-ERT2 nuclear 
translocation, cells were treated with 500 nM of 4-hydroxytamoxifen (4-OHT, Sigma) 
dissolved in absolute ethanol (Panreac). 
For G1/S synchronization using a double thymidine block, sub-confluent asynchronous 
MEFs were treated with 2mM thymidine (Sigma) for 12 hours, release with normal 
medium for 8 hours and treated again with 2mM thymidine for additional 12 hours.  
5.3 Beta-galactosidase staining  
Beta-galactosidase activity is considered one of the hallmarks of senescent cells due to the enhanced 
expression of the lysosomal protein GLB1, even though it does not seem to participate to the senescent 
phenotype induction. This activity is generally defined SA-βGal (Senescent associated β-galactosidase 
activity. 
105 MEFs grown at 3 % oxygen or 21% oxygen (5% CO2) have been plated at passage 5 
(~20 days from derivation) on 0.1% gelatine-coated slide chambers and analysed for beta-
galactosidase positivity using the Senescence β-Galactosidase Staining Kit (Cell 
Signaling). 
5.4 Growth curves, colony and foci formation assays 
Growth curve are the most useful tools to measure cellular proliferation. We used an unbiased method 
consisting in plating the entire curve in the same moment and collecting the plates day by day detecting the 
number of cells by staining (Crystal violet). This allows you to physically detect the cells (and their growth) 
also by eyes at the end of the curve, and to easily quantify the growth by spectrophotometer detection of the 
cell-bound crystal violet (that is proportional to the number of cells) resuspended in a fix volume of acetic 
acid. 
Colony assays are standard assay used to measure the ability of the cells to growth when they are extremely 
diluted in the dish. This ability is peculiarity of immortalized and transformed cells that are largely 
insensitive to the absence of cell to cell contacts (which in wild type MEFs is fundamental for proper 
proliferation) and can growth in a clonal like manner. 
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Foci formation assay is one of the gold-standard methods to test the transformed phenotype of the cells that, 
in the case of MEFs and other cell types, consists in the ability to growth in an anchorage-independent 
manner forming so called foci. Historically this methodology was applied to test the transformation ability of 
pieces of DNA transfected in NIH/3T3 immortalized MEF. Oncogenic DNA were then analysed to find new 
putative oncogenes. This method is quite low efficient, firstly because is based on transient transfection, and 
secondly because the DNA oncogenic potential was unknown. In our study we stably expressed well-known 
potent oncogenes to transform our MEF (H-RASV12 and c-myc) therefore virtually all the cells are stably 
transformed. Then we had to adapt that method using a mixed population of immortalized and transformed 
MEF that allowed us to discriminate individual foci that otherwise would have not been distinguishable. 
All growth curves have been generated by plating 5x104 cells/well in a 6 wells plate or 
3x104 cells/well in a 12 wells plate in triplicate for each day of the growth curve. Each day 
of the growth curve, cells have been fixed using cold (+4°C) 4% formaldehyde buffered at 
pH 6,9 (Panreac) for 10 minutes at RT, washed twice with distilled water and air-dried. At 
the end of each curve single wells were stained with a 0,1% w/v solution of crystal violet 
(Sigma) for 30 minutes at RT. Plates were washed 4 times in water and dried O/N. Crystal 
violet was solubilized using 10% acetic acid (Carlo Erba) and the absorbance measured at 
λ=590nm. All growth curves were plated 1 week after OHT administration for the 
conditional KO MEFs and 2 days after antibiotic selection for the lentiviral infected cells. 
All the growth curves presented are representative of at least 3 independent experiments.  
Colony formation assays were performed with triplicate plating of 104 cells in a 10 cm 
dish. After 12-14 days cells were fixed and stained with crystal violet as described for the 
growth curves.  
Foci formation was obtained by plating 4x106 SV40ER-immortalized MEFs with 2x105 
SV40ER H-RASV12 transformed MEFs in a 10 cm dish. After 15-20 days cells have been 
fixed with 10% formaldehyde for 30 minutes at RT, stained with a 4% Giemsa (Sigma) 
solution in 1XPBS for 2 hours at RT, washed 4 times in water and air dried O/N. All the 
foci formation assays presented are representative of at least 2 independent experiments.  
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Colonies and foci counting have been performed with imageJ counting particles tools. 
Equal threshold settings and other parameters have been applied to all images. 
5.5 Immunoblots 
This is a standard procedure that allows detecting the abundance levels of proteins or proteins PTM from a 
cell lysate. 
Immunoblots have been performed as described elsewhere253. All blots including 
conditional knockout or infected MEFs have been carried out with protein lysates prepared 
7-8 days after 4-OHT administration or after two days from antibiotic selection for the 
infected cells. A list of antibodies is available in Table 1. 
5.6 BrdU FACS analysis 
This is a standard procedure that allows locating the cells in a phase of the cell cycle. 
Cells grown in the presence of 33µM BrdU for the indicated time were fixed with 75% 
ethanol (Panreac), permeabilized with 2N HCl (Panreac) for 30 minutes at RT and the pH 
equilibrated using 0,1M BORAX (Sigma) for 2 minutes. Cells were incubated with a 
mouse anti-BrdU antibody (BD) in 1% BSA/1X PBS for 1h at room temperature, washed 
and stained with a donkey anti-mouse FITC-conjugated antibody (Jackson). Stained cells 
were treated with RNAse A (Sigma) followed by DNA staining with 2,5 ug/ul propidium 
iodide (Sigma) O/N at 4ºC. BrdU intensities have been were acquired on FACS Calibur 
and analyzed using the FLOW JO software. Antibodies details are available in Table 1. 
5.7 Viral transductions 
Retro and Lentiviral transductions are very useful tools to stably express a protein in the cell 
Lentiviral transduction has been carried out by infection with a VSV-G pseudotyped 
lentivirus. Viral particles were produced by calcium-phosphate transfection of 106 293T 
cells in a 10 cm dish using 10ug of viral delivery vector, 3 µg of VSV-G and 6µg of Δ8.2 
packaging vectors per dish. 36 hours post transfection, the supernatant containing viral 
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particles was collected, 0.45µm filtered and added to 5x105 MEFs that were plated the day 
before on a 10cm dish. 2 rounds of infection (~8 hours per day) were carried out for each 
plate in the presence of 5ug/mL of polybrene (Sigma) followed by selection with the 
appropriate antibiotic selection.  
Retrovarial transductions were carried out by transfecting 10ug of the viral vector in 106 
Phoenix-Eco cells plated on a 10 cm dish. Infections were carried out as for lentiviruses 
with the introduction of two additional round of infection (two per day) without polybrene. 
A list of the vectors used for infections is available in Table 2. 
5.8 Embryos development 
Mouse embryo development is a high complex physiological process that requires and involves several and 
different biological functions among which, one of the most important is certainly cellular proliferation. 
However it’s very difficult to correlate embryos defects to a precise problem in a biological process involved. 
Therefore this analysis generally results in correlations between the phenotype/s observed and the biological 
processes altered. 
To obtain Suz12 -/-, Ink4a/Arf -/- double KO embryos, Suz12 +/-, Ink4a/Arf -/- have been 
mated and embryos analysed at the indicated time from the detection of vaginal plugs 
(referred as 0.5 dpc). Each embryo’s morphology was recorded with a stereomicroscope 
and genotyped as previously described251. 
5.9 Nude mice tumours formation 
Nude mice tumours formation is the gold standard methodology that formally proves the oncogenic ability of 
the cells. Moreover it can be used as a surrogate in vivo tumour development system that allows monitoring 
a certain number of parameters such as tumour growth rate. 
106 cells subcutaneously injected in each flank of 6 weeks-old nude athymic mice (nu/nu) 
(Charles River laboratories) in 100µl of 1XPBS. Masses growth was measured every 2-3 
days from the injection using an electronic calliper. Mice were sacrificed after 14-15 days 
from injection; the tumour masses isolated and weighted using an electronic scale.  
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5.10 Immunofluorescence 
This is a standard technique that allows to spatially locating in single cells the antigens you are interested in 
(such as proteins or nucleotide analogue in genomic DNA in our case). Moreover using the confocal 
microscope it is possible to test the colocalization of 2 or more antigens on the same focal plane with a 
resolution of 200-400nm. 
Indicated MEFs were seeded on 0.1% gelatinized glass coverslips and treated as indicated. 
To prepare nuclei on coverslips, cells were treated with cold pre-extraction buffer (10mM 
Tris HCl pH 7,6, 100mM NaCl, 2mM MgCl2, 0,3M sucrose and 0,25% Igepal) for 10 
minutes at +4°C.Nuclei were fixed at -20°C with 100% methanol (Panreac)  for 10 
minutes. Nuclei were further incubated with 20mU/µl of DNAseI (NEB) for 30 minutes at 
37°C to unmask incorporated BrdU. Fixed nuclei were incubated with primary antibodies 
diluted in 0.1% tween-TBS for 1h at RT, washed and incubated with secondary antibodies 
conjugated with different fluorophores. Nuclei were counterstained with DAPI and 
embedded in anti-fade containing glycerol (DABCO). 
Images were acquired using a Leica SP2 confocal microscopy. Mender’s co-localization 
coefficient was calculated on the entire images Z-stacks using the jacop tool of the Image J 
software.  
The list of antibodies and reagents is available in Table 1.  
5.11 Microarray expression analyses 
Microarray analysis on cDNA is commonly used to look at transcriptome variations among different 
biological samples. It is limited by the probes present in the array. 
RNA from two independent OHT or EtOH treatments of Ezh2fx/fx Ink4/Arf-/- MEF and 
the RNA from one OHT or EtOH treatment in MEF Ezh2fx/fx were hybridized 
independently to Mouse Gene 1.0 ST Affymetrix Arrays. Signals were RMA normalized 
and analyzed using Affy and limma bioconductor packages in R. Affy IDs were annotated 
using mogene10sttranscriptcluster.db package. Probeset with a Log2 (FC)>0.5 expression 
  66  
difference and a p-value less than 0.05 were considered as differentially expressed. The 
microarray data have been deposited at the GEO database (GSE48520).  
5.12 DNA combing 
DNA combing is a high specialized technique allowing you to directly visualize replication forks. This 
technique supplies one of the deepest (together with few other techniques like electron microscopy) way to 
finely analyse replication forks on different points of view. With this methodology it is possible to measure 
the replication forks speed, their symmetry degree in respect of an origin of replication, furthermore it is 
possible to stimate inter-origin distances and indirectly the number of origins of replication. 
DNA combing has been performed as previously described elsewhere240, 254. Briefly, cells 
were sequentially labelled for 20 min. with 25 μM IdU followed by 20 min. of 200 μM 
CldU incubation in the cell culture medium. Labelled cells were embedded in agarose 
plugs, proteinase K-treated, DNA extracted and combed on silanised coverslips. DNA 
fibres were incubated with a mouse anti-ssDNA antibody (MAB3034, Chemicon) followed 
by anti-mouse IgG2a Alexa 546 coupled secondary antibody staining (Molecular Probes). 
Incorporation of halogenated nucleotides was detected with specific antibodies (IdU: 
mouse anti-BrdU, Becton Dickinson; CldU: rat anti-BrdU, Abcam) and visualized with 
appropriate secondary antibodies (goat anti-mouse IgG1-Alexa Fluor 647, Molecular 
Probes; goat anti-rat- Alexa Fluor 488, Molecular Probes). Images have been acquired 
automatically with a spinning disk confocal microscope and the individual labelled DNA 
molecules manually measured with ImageJ. The list of antibody used in the analyses is 
available in Table 1. 
5.13 Hematopoietic stem cells and methylcellulose assay 
Methylcellulose assay is a gold standard technique that allows measuring the self-renewal capability of stem 
cells or progentiors cells (like in this case HSCs or progenitor cells). It is possible to measure the number of 
colonies and the number of cells per colony (colony size). Transformed HSCs (cancer HSCs) will result in 
the formation of higher number of colonies and larger size compare to normal HSCs. 
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Bone marrow cells collected from the femur and tibia of Ring1a-/-; Ring1b fx/fx R26CRE-
ERT2 mice have been subject to lineage negative (Lin-) enrichment using Hematopoietic 
Progenitor Enrichment Kit (StemCell Technologies) to remove cells expressing 
differentiation antigens. Lin- cells have been put in culture in DMEM (Lonza) 
complemented with 10% FBS for mouse myeloid colony forming cell (scFBS StemCell 
Technologies), 100ng/ml SCF (Peprotech), 20ng/ml recombinant IL3 (Peprotech), 20ng/ml 
IL6 (Peprotech), and infected using a lentiviral expressing vector EF1a-cMYC. After two 
rounds of spin-infection using RetroNectin-coated plates and three days of 2ug/mL 
puromycin selection, 5x103 Lin- cells were plated in each 35mm dish mixed to 1,2ml of 
Metho cult GF M3434 (StemCell Technologies) in the presence of either 500nM OHT 
(Sigma) or ethanol (Panreac) as control. After 7 days, colonies were counted and 5x103 
cells derived from the colonies were re-plated two additional times in methylcellulose.  
5.14 Tip tail fibroblasts 
Tip tail fibroblasts are regarded as adult mice derived fibroblasts. Their characteristics (morphology, growth 
rate, etc.) are globally very similar to MEF ones. 
Mice Ink4a/Arf -/-; Ezh2 fx/fx have been sacrificed and 4-5 cm of the tail has been cut and 
collected in cold 1XPBS (Lonza). After sterilization (with ethanol), the tail has been 
accurately dried off and incised with a razor for skin removal. The tail has been diced in 
little pieces then plated in 6 well- 0.1% gelatin-coated plates in the same medium described 
for MEFs. 
5.15 Tandem affinity purification  
This type of protein purification is used to improve the quality and the clearness of single step tag-protein 
purification. The FLAG tag is a commonly used to identify and isolate overexpressed proteins. The Avi tag 
consists in a peptidic sequence that could be identify by a bacterial enzyme called Bir-A that specifically 
biotinylate a lysine residue of the Avi peptidic sequence. This allows the efficient biotynilation of your Avi-
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tagged protein in cells that express the BirA enzyme. Furthermore, performing the second purification step 
using streptavidin coated beads eliminate antibodies chains which are usually responsible of the noise in 
later analyses (i.e. mass spectrometry). 
To identify protein complexes interacting with proteins of interest, tandem (double-step) 
affinity purifications were performed with Flag-Avi-Ring1b and Flag-Avi-Eed BirA MEF 
cell lines, as well as with Flag-Avi-empty BirA MEF, that served as negative control in 
both cases. All protein purifications were carried out on nuclei of the correspondent cell 
lines, prepared by 20 min swelling in nuclear prep buffer (10mM Tris, 100mM NaCl, 2mM 
MgCl2, 0.3 M Sucrose, 0.25 % v/v Igepal) at 4 °C. Nuclei were lysed in high salt buffer 
(50mM Tris–HCl pH 7.5, 300mM NaCl, 10% glycerol, 0.25% Igepal) with fresh addition 
of a protease inhibitor cocktail (Roche). The tandem affinity purifications were performed 
by incubating about 20 mg of nuclear protein extracts with 200 µl of packed agarose beads 
covalently linked with anti-Flag antibody (anti-Flag agarose beads, Sigma-Aldrich, cat. 
A2220) over night (ON) at 4 °C on a rotating platform. Beads were washed six times in 
minimum ten beads volumes of high salt buffer at 4°C and protein complexes eluted for 30 
min with 0.5 mg/ml of Flag peptide (DYKDDDDK) in high salt buffer at 20°C four times. 
Eluates were pulled and further precipitated with 100 µl of streptavidin magnetic beads 
(Invitrogen, cat. 656-01) ON at 4 °C. Streptavidin beads were washed six times as before at 
4°C and protein complexes eluted with Laemmli sample buffer (Invitrogen). 
5.16 Proteomic analysis 
Analysis of proteins isolated from tandem purifications was done by mass spectrometry (MS). MS is an 
analytical technique used not only in proteomic studies that produces spectra of the masses of the atoms or 
molecules present in a sample of material. A mass spectrometer is constituted by three fundamental 
instruments, corresponding to three specific functions: an ion source, a mass analyzer and a detector. Thus, 
the sample is first ionized, then correspondent ions are separated according to mass/charge ratio, and finally 
the detector converts signals received in spectra of the relative abundance of ions as a function of the mass-
to-charge ratio. The atoms or molecules can be identified by correlating known masses to the identified 
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masses. In addition, two steps of mass analyzing can be done to refine the results, and in this case it is called 
tandem mass spectrometry or MS/MS. In our proteomic approach, briefly, proteins were separated by gel 
electrophoresis and enzymatically in gel-digested, producing a peptides mixture then  separated by liquid 
chromatography before injecting into the mass spectrometer.  
Protein digestion produces peptides earning each one a typical spectrum; in addition, some 
peptides are produced uniquely by digestion of specific proteins, therefore indicating 
without any doubt the presence of such proteins in the sample. Combining these features 
with computational tools, we were able to match peptide spectra with the proteins to which 
they belong.  
Hence, eluted proteins obtained by tandem purifications were separated by 1D SDS–
PAGE, using 4–12% NuPAGE Novex Bis–Tris gels (Invitrogen, cat. NP0321BOX) and 
NuPAGE® MES SDS running buffer (Invitrogen, cat. NP0002) according to 
manufacturer’s instructions. In order to check purification efficiency, 10% of the whole 
eluate was separated on a gel and stained using SilverQuest staining kit (Invitrogen, cat. 
LC6070). The remaining part of the purification was separated on an independent gel and 
stained with Coomassie Blue using a Colloidal Blue Staining Kit (Invitrogen, Cat. 
LC6025). Samples were digested with trypsin (Promega). Briefly, the gel bands were cut 
and then washed four times with 50mM ammonium bicarbonate, 50% ethanol and 
incubated with 10mM DTT in 50mM ammonium bicarbonate for 1 h at 56°C for protein 
reduction. Alkylation step was performed incubating the sample with 55mM 
iodoacetamide in 50mM ammonium bicarbonate for 1 h at 25°C in the dark. Gel pieces 
were washed two times with a 50mM ammonium bicarbonate, 50% acetonitrile solution, 
dehydrated with 100% ethanol and dried in a vacuum concentrator. Digestion was 
performed using 12.5 ng/ml trypsin in 50mM ammonium bicarbonate and incubated for 16 
h at 37°C for protein digestion. Supernatant was transferred to fresh tube, and the 
remaining peptides were extracted by incubating gel pieces two times with 30% 
acetonitrile (MeCN) in 3% trifluoroacetic acid (TFA), followed by dehydration with 100% 
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acetonitrile. The extracts were combined, reduced in volume in a vacuum concentrator, 
desalted and concentrated using RP-C18 StageTip columns and the eluted peptides used 
for mass spectrometric analysis.  
Peptide mixtures were separated by nano-LC/MSMS using an Agilent 1100 Series 
nanoflow LC system (Agilent Technologies), interfaced to a 7-Tesla LTQ-FT-Ultra mass 
spectrometer (ThermoFisher Scientific, Bremen, Germany). The nanoliter flow LC was 
operated in one column set-up with a 15-cm analytical column (75 mm inner diameter, 350 
mm outer diameter) packed with C18 resin (ReproSil, Pur C18AQ 3 mm, Dr Maisch, 
Germany). Solvent A was 0.1% FA and 5% ACN in ddH2 O and Solvent B was 95% CAN 
with 0.1% FA. Samples were injected in an aqueous 0.1% TFA solution at a flow rate of 
500 nl/min. Peptides were separated with a gradient of 0–40% Solvent B over 90 min 
followed by a gradient of 40–60% for 10 min and 60–80% over 5 min at a flow rate of 250 
nl/min. The mass spectrometer was operated in a data-dependent mode to automatically 
switch between MS and MS/MS acquisition. In the LTQ-FT full scan MS spectra were 
acquired in a range of m/z 300–1700 by FTICR with resolution r =100 000 at m/z 400 with 
a target value of 1 000 000. The five most intense ions were isolated for fragmentation in 
the linear ion trap at a target value of 5000. The nanoelectrospray ion source (Proxeon, 
Odense, Denmark) was used with a spray voltage of 2.4 kV. For the purification carried 
out on Flag-Avi-empty, Flag-Avi-Ring1b and Flag-Avi-Eed cells, collision gas pressure 
was 1.3 millitorrs and normalized collision energy using wide band activation mode was 
35%. Ion selection threshold was 250 counts with an activation q=0.25. The activation time 
of 30 ms was applied in MS2 acquisitions.  With Flag-Avi-empty Flag-Avi-Ring1b and 
Flag-Avi-Eed cells purifications, no sheath and auxiliary gases were used and capillary 
temperature was set to 180ºC. The activation time of 30 ms was applied in MS/MS 
acquisitions. 
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5.17 Protein identification 
This bioinformatic methodology allows retrieving information on the identities of the proteins that were 
interacting with your protein of interest using specific algorithm and protein databases. 
Data analysis and assigning sequences were done using MASCOT to identify proteins 
belonging to purifications from Flag-Avi-empty Flag-Avi-Ring1b and Flag-Avi-Eed cells. 
The raw data from LTQ-FT Ultra were converted to mgf files using Raw2MSM 
software255. The MS/MS peak lists were filtered to contain at most six peaks per 100 
Dalton intervals and searched by Daemon (version 2.2.2, Matrix Science) against a 
concatenated forward and reversed version of IPI mouse database (version 6.63) (56 073 
sequences; 25 214 299 residues)256. This database was complimented with frequently 
observed contaminants (porcine trypsin and human keratins) and their reversed sequences 
as well. Search parameters were: an initial MS tolerance of 7 ppm, a MS/MS mass 
tolerance at 0.5 Da and full trypsin cleavage specificity, allowing for up to two missed 
cleavages. Carbamidomethylation of cysteine was set as a fixed modification and variable 
modifications included oxidation on methionine and acetylation on N-terminus of proteins. 
We accepted peptides and proteins with a false discovery rate (FDR) of <1%, estimated 
based on the number of accepted reverse hits257.  
Differently, protein identification was performed using Andromeda search engine for 
purifications done with Flag-Avi-empty and Flag-Avi-Ring1b and Flag-Avi-Eed cells. The 
raw data from LTQ-FT Ultra were converted to mgf files using Raw2MSM software255. 
Raw data files were analyzed using MaxQuant software (version 1.3.0.1) as described255. 
Parent ion and MSMS spectra were searched against a database containing 87,061 protein 
sequences obtained from the human IPI protein database version 3.68 and 248 protein 
sequences of commonly observed contaminants using Andromeda search engine258. 
Spectra were searched with a mass tolerance of 7 ppm in MS mode and 0.5 Da in MS/MS 
mode, strict trypsin specificity and allowing up to two missed cleavage sites. Cysteine 
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carbamidomethylation was searched as a fixed modification, whereas N-terminal protein 
acetylation, methionine oxidation were searched as variable modifications. We accepted 
peptides and proteins with a false discovery rate (FDR) of <1%, estimated based on the 
number of accepted reverse hits258. Intensity based absolute quantification score (iBAQ) 
intensity values as calculated by MaxQuant were used to estimate relative abundance of 
proteins in each experiment259. 
5.18 Statistical analyses 
Statistical analyses were carried out with R packages. p-values for growth curves and in 
vivo tumour growth were determined by computing the area under curve (AUC) using 
kulife package applied for student's t-test between AUC's of two samples or groups. p-
Values for colonies and foci counts have been generated using a paired t-test. p-values for 
tumour masses weights were generated using a Mann-Whitney test. All p-Values obtained 
for DNA combing analyses have been determined with a chi-squared test. 
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5.19 Table 1 
Reagent Company Catalogue # 
Working        
dilution                    
IB 
Working        
dilution                    
IF 
Working 
dilution 
FACS 
anti-p16 Santa Cruz sc-1207 (M-156) 1:2000     
anti-p19/Arf abcam ab80 1:1000     
anti-β-tubulin Santa cruz sc-9104 (H-235) 1:1000     
anti-p21 DakoCytomation M7202 (SX118) 1:1000     
anti-p53 home made hybridoma 1:5     
anti-p53 phospho-S18 Cell Signaling 9284S 1:500     
anti-Ezh2 home made hybridoma (BD43) 1:5     
anti-Suz12 Santa Cruz sc-46264 (P-15) 1:1000     
anti-Eed home made hybridoma (AA19) 1:5     
anti-H-RAS Santa Cruz sc-520 (C20) 1:1000     
anti-SV40 T Ag Santa Cruz sc-148 (Pab 108) 1:1000     
anti-H3K27me3 Cell Signaling 9733S 1:500     
anti-H3 abcam ab1791 1:10000     
anti-Ring1b MBL D139-3 (3-3) 1:1000   1:100 
anti-H2AK119ubq Cell Signaling 8240S 1:2000     
anti-H2A Cell Signaling 12349 1:5000     
anti-Vinculin home made purified 1:50000     
anti-BrdU BD 347580   1:5 1:5 
anti-Suz12 Cell Signaling 3737S   1:50   
anti-53bp1 Millipore NB 100-304   1:500   
DAPI Sigma D9542   0.5ug/mL   
Propidium iodide Sigma P4170     50ug/mL 
anti-ssDNA Chemicon MAB3034   1:100   
anti-CldU abcam ab6326   1:200   
HRP-goat-anti-rabbit Dako P0448 1:5000     
HRP-goat-anti-mouse Dako P0447 1:5000     
HRP-rabbit-anti-goat Dako P0449 1:2000     
Alexa fluor 488 
conjugated donkey-
anti-rabbit 
Invitrogen A21206   1:100   
Dylight 649 
conjugated donkey-
anti-mouse 
Jackson 
Immunoresearch 715495151   1:500   
FITC conjugated 
donkey-anti-mouse 
Jackson 
Immunoresearch 715095150     1:50 
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Vector name viral type hairpin sequence
H1P-UbqC-HYGROGFP Empty lentiviral 
H1P-UbqC-HYGROGFP shSzu12 lenitiviral AAGCTGTTACCAAGCTCCGTG
LKO shLuc puromycin lentiviral 
CCGGCGCTGAGTACTTCGAAA
TGTCCTCGAGGACATTTCGAA
GTACTCAGCGTTTTTG
LKO shEed puromycin lenitiviral
CCGGTCTTGCTAGTAAGGGCA
CATACTCGAGTATGTGCCCTT
ACTAGCAAGATTTTTG
EF1α-c-MYC puromycin lentiviral 
pWZL SV40 ER neomycin retroviral
pBabe Empty puromycin retroviral
pBabe H-RASV12 puromycin retroviral
EF1α-Avi-Flag-Ring1b puromycin lentiviral 
EF1α-Avi-Flag-Eed puromycin lentiviral 
5.20 Table 2 
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